2017N322544_01 CONFIDENTIA L
GlaxoSmithKline group of companies 205820
1TITLE PA GE
Protocol Title: A Two Part Study  to Assess i) the Relative Bioavailability  and Food 
Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and 
ii) the Safety and Pharmacokinetics of Repeated Once -Daily  Doses of Non booste d 
GSK2838232
Protocol Number : 205820
Short Title : A two- part study  to i) compare a tablet and capsule formulation of 
GSK2838232 with and without food, and ii) assess the safet y and pharmacokinetics of 
repeated once -daily doses of GSK2838232 without ritonav ir.
Compound Number: GSK2838232
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Medical Monitor Name and Contact Information can be found in the Study  Referen ce 
Manual
Regulatory Agency Identifying Number(s): IND 116,094
Approval Date: 18-JUL - 2017
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
PPD
PPD
PPD
PPD
PPD
2017N322544_01 CONFIDENTIA L
205820
4PROTOCOL AMENDMENT SUM MARYOF C HANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 1 18-JUL-2017
Original P rotocol 09-JUN-2017
Amendment 1 18-July-2017
Overall Rationale for the Amendment: The protocol was amended to include an 
assessment of neurops ychiatic adverse events at each AE enquiry  as well as a statement 
to inform FDA of an y grade 2 or higher alter ation in personality -behavior or in mood or 
altered mental status within 7 day s, per FDA request.
Minor ty pographical error s werealso amended in the Schedule of Assessments , the 
Exclusion Criteria and the Study  Assessment and Procedures. 
Section # and 
NameDescription of Change Brief Rationale
2. SCHEDULE 
OF 
ASSESSMENTSA footnote was added to Table 
2 and Table 3 to allow 
assessment of neuropsychiatric 
adverse events.
The “X” in the column for AE 
collection in the screening 
period for Part 2 was delet ed.This change was made per FDA 
request .
Typographical error
6.2. Exclusion 
CriteriaPR Interval range was 
corrected.Typographical error
9.2.1. Time Period 
and Frequency for 
Collecting Adverse 
Event and Serious 
Adverse Event 
InformationA sentence w as added to 
indicate sponsor’s plan to 
inform FDA within 7 days of 
grade 2 or higher alteration in 
personality- behavior or mental 
status.
AEs collection time was 
changed to from the start of 
treatment.This change was made per FDA 
request.
Typographic al error
2017N322544_01 CONFIDENTIA L
205820
5TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 4
1.SYNOPSIS ............................................................................................................... 8
2.SCHEDULE OF ASS ESSMENTS .......................................................................... 13
3.INTRODUCTION .................................................................................................... 19
3.1. Study Rationale .......................................................................................... 19
3.2. Background ................................................................................................ 19
3.2.1. Pharmacokinetic Summary .......................................................... 19
3.3. Benefit/Risk Assessment ............................................................................ 21
3.3.1. Risk Assessment ......................................................................... 22
3.3.2. Benefit Assessment ..................................................................... 27
3.3.3. Overall Benefit: Risk Conclusion .................................................. 27
4.OBJECTIVES AND ENDPOINTS ........................................................................... 28
5.STUDY DESIGN .................................................................................................... 29
5.1. Overall Design ............................................................................................ 29
5.2. Number of Participants ............................................................................... 32
5.3. Participant and Study Completion ............................................................... 32
5.4. Scientific Rationale for Study Design .......................................................... 32
5.5. Dose Justification ........................................................................................ 33
6.STUDY POPULATION ........................................................................................... 33
6.1. Inclusion Criteria ......................................................................................... 34
6.2. Exclusion Criteria ........................................................................................ 36
6.3. Lifestyle Restrictions ................................................................................... 38
6.3.1. Meals and Dietary Restrictions .................................................... 38
6.3.2. Caffeine, Alcohol, and Tobacco ................................................... 39
6.3.3. Activity ......................................................................................... 40
6.4. Screen Failures ........................................................................................... 40
7.TREATMENTS ....................................................................................................... 40
7.1. Treatments Administered ............................................................................ 40
7.1.1. Medical Dev ices........................................................................... 42
7.2. Dose Modification ....................................................................................... 42
7.3. Method of Treatment Assignment ............................................................... 42
7.4. Blinding ....................................................................................................... 42
7.5. Preparation/Handling/Storage/Accountability.............................................. 43
7.6. Treatment Compliance................................................................................ 44
7.7. Concomitant Therapy .................................................................................. 44
7.8. Treatment after the End of the Study .......................................................... 44
8.DISCONTINUATION CRITERIA ............................................................................. 45
8.1. Discontinuation of Study Treatment ............................................................ 45
8.1.1. Liver Chemistry Stopping Criteria ................................................ 45
8.1.2. QTc Stopping Criteria .................................................................. 46
8.1.3. Tempora ry Discontinuation .......................................................... 46
2017N322544_01 CONFIDENTIA L
205820
68.1.4. Rechallenge ................................................................................. 46
8.2. Withdrawal from the Study .......................................................................... 46
8.3. Lost to Follow Up ........................................................................................ 46
9.STUDY ASSESSMENTS AND PROCEDU RES ..................................................... 47
9.1. Efficacy Assessments ................................................................................. 48
9.2. Adverse Events ........................................................................................... 48
9.2.1. Time Period and Frequency for Collecting Adverse Event 
and Serious Adverse Event Information ....................................... 48
9.2.2. Method of Detecting AEs and SAEs ............................................. 49
9.2.3. Follow -up of AEs and SAEs ......................................................... 49
9.2.4. Regulatory Reporting Requirements for SAEs ............................. 49
9.2.5. Pregnancy ................................................................................... 50
9.2.6. Total Blood Volume ..................................................................... 50
9.3. Treatment of Overdose ............................................................................... 50
9.4. Safety Assessments ................................................................................... 51
9.4.1. Physical Examinations ................................................................ .51
9.4.2. Vital Signs .................................................................................... 51
9.4.3. Electrocardiograms ...................................................................... 51
9.4.4. Holter Monitoring ......................................................................... 52
9.4.5. Clinical Safety Laboratory Assessments ...................................... 52
9.5. Pharmacokinetics ....................................................................................... 53
9.5.1. Blood sample collection ............................................................... 53
9.5.2. Sample analysis ........................................................................... 53
9.6. Pharmacodynamics .................................................................................... 53
9.7. Genet ics..................................................................................................... 53
9.8. Biomarkers ................................................................................................ .53
9.9. Health Economics OR Medical Resource Utilization and Health 
Economics .................................................................................................. 53
9.10. DATA MANAGEMENT ................................................................................ 54
10.STATISTICAL CONSIDERATIONS ........................................................................ 54
10.1. Sample Size Determination ........................................................................ 54
10.2. Populations for Analyses ............................................................................ 55
10.3. Definition of Baseline .................................................................................. 55
10.4. Statistical Analyses ..................................................................................... 55
10.4.1. Safety Analyses ........................................................................... 56
10.4.2. Pharmacokinetic Analyses ........................................................... 56
10.4.2.1. Relative Bioavailability ................................................ 58
10.4.2.2. Food Effect ................................................................ .58
10.4.2.3. Steady State Assessments ......................................... 58
10.4.2.4. Accumulation .............................................................. 58
10.4.3. Efficacy Analyses ......................................................................... 58
10.4.4. Other Analyses ............................................................................ 59
10.4.5. Interim Analyses .......................................................................... 59
11.REFERENCES ....................................................................................................... 60
12.APPENDICES ........................................................................................................ 61
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 61
12.2. Appendix 2: Clinical Laboratory Tests ......................................................... 63
2017N322544_01 CONFIDENTIA L
205820
712.3. Appendix 3: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 64
12.4. Appendix 4: Division of AIDS Table For Grading The Severity of
Adult and Pediatric Adverse Events ............................................................ 67
12.4.1. Total Bilirubin Table for Term and Preterm Neonates: ............... 106
12.5. Appendix 5: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Foll ow-up, and Reporting ..................................... 108
12.5.1. Definition of Adverse Events ...................................................... 108
12.5.2. Definition of Serious Adverse Events ......................................... 109
12.5.3. Recording Adverse Events and Serious Advers e Events ........... 110
12.5.4. Evaluating Adverse Events and Serious Adverse Events ........... 111
12.5.5. Reporting of Serious Adverse Events to GSK ............................ 112
12.6. Appendix 6: Contraceptive G uidance and Collection of Pregnancy 
Information ................................................................................................ 113
12.7. Appendix 7: Study Governance Considerations ........................................ 117
2017N322544_01 CONFIDENTIA L
205820
81. SYNOPSIS
Protocol Title: A Two Part Study  to Assess the Relative Bioavailability  and Foo d Effect 
of a Novel Tablet Formulation of Boosted -GSK2838232 Compared to Capsule as well as 
the Safet y and Pharmacokinetics of Repeated Once -Daily Doses of Non -boosted 
GSK2838232
Short Title: A two- part study  to i) compare a tablet and capsule formulation of 
GSK2838232 with and without food, and ii) assess the safet y and pharmacokinetics of 
repeated once -daily doses of GSK2838232 without ritonavir.
Rationale:
This will be a two- part study  design that will confirm the acceptability  of a tablet 
formulation in healthy  participants for future clinical development of GSK2838232.
Part 1 is a relative bioavailability  study  that will assess single ritonavir (RTV) -boosted 
doses of a novel tablet formulation given with food (normal, approximately 30% fat) 
against the reference capsule formulation also given with food (Part 1A) and then will 
assess the impact of fasted conditions on the tablet performance (Part 1B).
Part 2 is a study  of non -boosted GSK2838232, given as once- daily tablet doses for 
11days in a separate cohort of participants, assuming the tablet performance is 
considered acceptable from Part 1A.  The dose of GSK2838232 used in Part 2 will be 
confirmed after Part 1A but is likely  to be, and will not exceed, 500 mg once dail y (QD) 
as tablets.  
Objectives a nd Endpoints:
Part 1:
Objectives Endpoints
Primary
To assess the relative 
bioavailability  of a novel 
GSK2838232 tablet 
formulations versus the capsule 
formulation (Part 1A)AUC(0 -) and Cmax
To assess the effect of food on 
GSK2838232 exposure of the 
tablet formulation (Part 1A and 
Part 1B)AUC(0 -), Cmax, and tmax
2017N322544_01 CONFIDENTIA L
205820
9Objectives Endpoints
Secondary
To investigate the safety  and 
tolerability  of GSK2838232 
following single dose 
administration as tablets or 
capsules, with RTVGSK2838232 safet y parameters: 
adverse events; absolute values and 
changes over time of clinical laboratory  
evaluations (hematology , clinical 
chemistry, urinal ysis), vital signs, and 
12-lead electrocardiogram (ECG) 
parameters from pre -dose values
To characterize the 
pharmacokinetics of 
GSK2838232 after 
admini stration of a novel tablet 
formulation and capsule 
formulation with food, and the 
tablet formulation given without 
foodtlag, tmax, t½, tlast, C24, and 
AUC(0 -t)
Part 2:
Objectives Endpoints
Primary
To assess the safet y of 
GSK2838232 administered as 
non-boosted once -daily  doses of 
a tablet formulation for 11 day sGSK2838232 safet y parameters: 
adverse events; absolute values and 
changes over time of clinical laboratory  
evaluations (hematology , clinical 
chemistry, urinal ysis), vital signs, and 
ECG paramete rs from pre -dose values
To assess the pharmacokinetics 
of GSK2838232 administered as 
non-boosted once -daily  doses of 
a tablet formulation for 11 day sDay 1 dose: AUC(0- ), Cmax, C , 
tmax, tlag
Day 11 dose: AUC(0- ), AUC(0 -), 
Cmax, C , tmax, t½, tlast
Secondary
To assess time to stead y-state of 
GSK2838232 when 
administered as non -boosted 
once -daily doses of a tablet 
formulation for 11 day sPre-dose concentrations on Day s 2 
to11
To assess accumulation of 
GSK2838232 when 
administered as non -boosted 
once -daily doses of a tablet 
formulation for 11 day sAccumulation ratios: Ro[AUC(0- )], 
R(Cmax), R(C )
AUC(0 -) = Area under the curve (Area under the plasma drug concentration -time curve from pre -dose to the end of 
the dosing interval at steady state); AUC(0 -inf)= Area under the concentration -time curve from time zero (pre -dose) 
extrapolated to infinite time; Cmax= Maximum observed concentration; t1/2= Apparent terminal phase half -life; tmax= 
Time of occurrence of Cmax; tlag= Lag- time (time delay between drug administration and first observed concentration 
above LOQ in plasma); AUC (0 -t) = Area under the concentration -time curve from zero up to a definite time t
2017N322544_01 CONFIDENTIA L
205820
10Overall Design
Part 1:
Part 1 is a relative bioavailability  study  that will further subdivide into t wo parts (Part 1A 
and Part 1B) ( Table 1 ).  In Part 1A, the safety  and pharmacokinetics (PK) of a novel 
tablet formulation of GSK2838232 will be evaluated in open label, randomized, 
cross -over fashion against the capsule formulatio n as reference.  Each actual treatment 
dose will be separated b y a minimum 10 -day washout period.  Part 1A will be studied in 
the fed state using a normal fat (i.e., approximately  30%) meal in all participants.  I n 
Part1B, the tablet will be administered in the fasted state to understand the impact of 
food on relative bioavailability .
Table 1 Treatment Groups in Part 1
SequenceN Part 1A Part 1B
Period 1 Period 2 Period 3
1 6 A B C
2 6 B A
1.All treatments in Part 1A to be admi nistered w ith RTV in a fed state, following two RTV pre -doses.
2.There w ill be a w ashout of at least 10 days between each Period.
3.Treatment A = GSK2838232 200 mg/r (as 4 x 50 mg) capsule formulation, fed, normal fat (i.e., 
approximately 30%) meal (reference) .
4.Treatment B = GSK2838232 200 mg/r (as 2 x 100 mg) tablet formulation, fed, normal fat (i.e., 
approximately 30%) meal.
5.Treatment C = GSK2838232 200 mg/r (as 2 x 100 mg) tablet, confirmed from Part 1A, fasted.
After completion of Part 1A, preliminary  PK data will be anal yzed, and a decision will be 
made based on safet y, tolerability , relative bioavailability  PK criteria, as well as 
feasibility  considerations, as to whether the tablet formulation will be used to conduct 
Part 1B (fasted) and Part 2.
Part 2:
Part 2 will evaluate non -RTV boosted GSK2838232, given as single daily  doses for 
11days in a separate cohort of participants (N=8; 6A/2P).  The placebo tablet supplied 
will not be identical to GSK2838232 and as such will be administered b y site staff via an 
opaque card/paper tube to facilitate the single blind (i.e., the Principal Investigator [PI] 
and the participants themselves will be blinded as to their treatment).  The dose chosen 
for Part 2 will depend upon the preliminary  results of the tablet in Pa rt 1A but is likely  to 
be, but will not exceed, 500 mg (i.e., 5 x 100 mg tablets) QD.  
2017N322544_01 CONFIDENTIA L
205820
11Number of Participants:
It is expected that a sufficient number of participants will be screened in order to enroll 
approximately  16health y participants to provide at least 12 evaluable participants 
through the three stud y periods for Part 1 and 10 healthy  participants to provide at least 8 
evaluable participants for the single stud y period of Part 2.
If participants prematurely discontinue the stud y, additional partici pants may be 
randomized and assigned to the same treatment sequence at the discretion of the Sponsor 
in consultation with the Investigator .
Treatment Groups and Duration:
GSK2838232 as tablets or capsules (at a 200 mg dose level) will be administered with 
100mg RTV, after two pre -doses of 100 mg RTV QD over 48 h.  The use of RTV 
priming is an aspect of GSK2838232 clinical development (specificall y relative 
bioavailability  studies) so far and allows a more accurate assessment of what will 
ultimately  happen in the repeat -dose clinical studies with GSK2838232 when 
administered with RTV.  In Part 2 of the stud y however, GSK2838232 will be 
administered unboosted and no RTV will be co- administered.
In both Part 1 and Part 2 participants will have a screening visi t within 30 days prior to 
first dose, a minimum 10- day washout period between doses (Part 1 only ), and a follow -
up visit 7 to 14 day s after the last dose.  The maximum duration of study  participation 
will be approximately  9 to 10 weeks for Part 1 and 8 to 9 weeks for Part 2.
2017N322544_01 CONFIDENTIA L
205820
12Study Schematic
Part 1
Part 2

2017N322544_01 CONFIDENTIA L
205820
132. SCHEDULE OF ASSESSMENTS
Please see Table 2andTable 3below for the Schedule of assessments for study  Parts 1 
and 2 respectivel y.
2017N322544_01 CONFIDENTIA L
205820
14Table 2 Schedule of A ssessments for Part 1A  and Part 1B: Single Dose RBA  Food
ProcedureScreening
(within 30 days of 
Day 1 -carried out 
over multiple days –
except as noted in 
footnotes)Periods 1 through 3 Follow -
up1
Day -3 Day -2 Day -1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 77-14 
days
24 h 48 h 72 h 96 h 120 h
Admission to Unit X2
Outpatient Visit X X
Informed Consent X
Medical/medication/
drug/alcohol history 
(Demographics)X
Full Physical Examination X
Brief Physical Examination X X X
Height, Weight, BMI X
Inclusion/Exclusion X
Vital signs3 X X X X X X X X
12 Lead ECG4 X X X X X X X
Echocardiogram5 X
Drug/alcohol/ cotinine screen X X
HbsAg, HCV, HIV tests X
Hem/Chem/Urine tests6 X X X X X X
Serum FSH (as appropriate) X
Troponin I7 X X X X X
24h Holter Monitoring8 X
Pregnancy test (women) X X X
Run-in Dosing with RTV X X
Dosing with GSK2838232+RTV X
PK Sampling9 X X X X X X
Adverse Event Review10 X X X X X X X X X
Con Med Review X X X X X X X X X X
Discharge from Unit11 X
Out Patient Visit X X X X X
2017N322544_01 CONFIDENTIA L
205820
15BMI=Body Mass Index; ECG =Electrocardiogram; FSH =Follicle Stimulating; HbsAg =Hepatitis B surface Antigen; HCV =Hepatitis C Virus; HIV =Human Immunodeficiency Virus; 
Hem/Chem =Hematology/Clinical Chemistry; RTV =Ritonavir; PK =Pharmaco kinetic(s); Con Med =Concomitant medications.
1. Follow -up Visit to take place after Treatment Period 2.
2. When participants stay in the unit across treatment periods, d rug/alcohol/cotinine screen and pregnancy test (women) are not required on Day -3 for later periods.
3. On Day 1, Blood pressure (BP) and Heart rate (HR) will be collected at pre -dose (triplicate) and single assessments at 1, 2, 4, 6, 8, 12, 24, 48, and 72 h post- dose.
4. On Day 1, 12 -lead ECG will be collected at pre -dose (triplicate), and single ass essments at 1, 2, 4, 6, 8, 12, 24, 48 and 72 h post- dose.
5. Echocardiograms must be within 100 days of Day 1.
6. Samples for Chemistry and Hematology:  Blood samples will be obtained after an 8 -hour fast.
7. Collect one troponin sample to be analyzed at local labo ratory.  A second sample will be collected, frozen and stored on site for potential high sensitivity troponin analysis.
8. 24-h Holter monitoring to be performed after confirming negative urine drug screen at screening, and must be within 30 days of D ay 1.  H olter monitoring on other days only if 
needed.
9. Plasma PK samples for bioanalysis for GSK2838232 will be collected pre -dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 
120 h post- dose.  Samples w ill be acidified with an equal volume of 50 mmol citrate acid buffer pH 4.0.
10. An AE enquiry will be made at each visit, participants will be asked if they have experienced any neuropsychiatric adverse ev ents, including psychosis or altered mental status.
(see guidance for grading Altered Mental Status in Appendix 4).
11. Participants may be discharged after all study procedures are completed.  Participants will be in house for PK blood samples on Day 3 (48 h), Day 4 (72 h), Day 5 (96 h) and 
Day6 (120 h) of both study periods.
2017N322544_01 CONFIDENTIA L
205820
16Table 3 Schedule of A ssessments for Part 2: Repeated Doses for 11 day s:
MeasurementScreening
(within 30 
days of Day 
1 -carried 
out over 
multiple days 
-except as 
noted in 
footn otes)Follow -
up 
Day
–1Day
1Day
2Day
3Day
4Day
5Day
6Day
7Day
8Day
9Day
10Day
11
0 hDay 
12
24 hDay 
13
48 hDay 
14
72 hDay 
15
96 hDay
16
120 
h7-14 
days 
after 
last 
dose
Admission to Unit X
Informed Consent X
Medical/medication/
drug/alcohol history 
(Demographics)X
Full Physical 
ExaminationX X
Brief Physical 
ExaminationX X
Height, Weight, BMI X
Inclusion/Exclusion X
Medical History X
Vital Signs1 X X X X X X X X X X X X X X X X X
12-lead ECG2 X X X X X X X X X X
Echocardiogram3 X
Drug/alcohol/ /cotinine 
ScreenX X
HbsAg, HCV, HIV 
TestingX
Hem/Chem tests4 X X X X X X X X X
Urinalysis X X X X X X X
Serum FSH (as 
appropriate)X
Troponin I5 X X X X X X X X
2017N322544_01 CONFIDENTIA L
205820
17MeasurementScreening
(within 30 
days of Day 
1 -carried 
out over 
multiple days 
-except as 
noted in 
footn otes)Follow -
up 
Day
–1Day
1Day
2Day
3Day
4Day
5Day
6Day
7Day
8Day
9Day
10Day
11
0 hDay 
12
24 hDay 
13
48 hDay 
14
72 hDay 
15
96 hDay
16
120 
h7-14 
days 
after 
last 
dose
24 h Holter Monitoring6 X
Pregnancy Test
(fema les)X X X
Dosing of GSK2838232 X X X X X X X X X X X
Plasma PK sampling7 X X X X X X X X X X X X X X X X
Adverse Event 
Assessment8X X X X X X X X X X X X X X X X X X
Concomitant 
MedicationsX X X X X X X X X X X X X X X X X X
Discharge from Unit X9
Out Patient Visit X X X X X
BMI=Body Mass Index; ECG =Electrocardiogram; FSH =Follicle Stimulating Hormone; HbsAg =Hepatitis B surface Antigen; HCV =Hepatitis C Virus; 
Hem/Chem =Hematolo gy/Clinical Chemistry; HIV =Human Immunodeficiency Virus; IP =Investigational Product; PK =Pharmacokinetic(s).
1. A single blood pressure (BP) and Heart rate (HR) assessment will be collected at screening and Day -1.  On Day 1 triplicate BP and HR will be collected at pre -dose and single 
assessments at 1, 4, 24, 48 and 72 h (Day 4) post -dose, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11 at pre -dose (triplicate), and single assessment at 1, 4, 24, 48 and 
72h post- dose, and at follow -up.
2. A single 12- Lead ECG will be collected at screening and Day -1.  On Day 1 triplicate 12 -Lead ECGs will be collected at pre -dose, and then single 12 -Lead ECGs at 1, 4 and 12 h 
post- dose.  Single 12 -Lead ECGs will be collected on Days 2, 3, 5, 8.  On Day 11 triplicate 12 -Lead ECGs will be collected pre -dose, and then single 12 -Lead ECGs collected at 1, 
4, 12 and 24 h post -dose and at follow -up.
3. Echocardiograms must be within 100 days of Day 1.
4. Samples for Chemistry and Hematology: Blood samples will be obtained after an 8 -hour fast.
5. Collect one troponin sample to be analyzed at local laboratory.  A second sample will be collected and frozen for potential h igh sensitivity troponin analysis.
6. 24-h Holter monitoring to be performed after confirming negative urine drug screen at screening, and must be within 30 days of Day 1.  Holter monitoring on other days only if 
needed.
2017N322544_01 CONFIDENTIA L
205820
187. Plasma PK samples for GSK2838232 will be collected as follows :  Day 1; pre -dose (within 15 minutes prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 h post -dose 
(prior to Day 2 dose).  Days 3 to 10 pre -dose (within 15 minutes prior to dosing).  Day 11; pre -dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 
36, 48, 72, 96 and 120 h post -dose.  Samples will be acidified with an equal volume of 50 mmol citrate acid buffer pH 4.0.
8. An AE enquiry will be made at each visit, participants will be asked if they have experienced any neuropsychiatric adverse ev ents, including psychosis or altered mental status.
(see guidance for grading Altered Mental Status in Appendix 4).
9. Participants will be discharged after all study procedures are completed on the morning of Day 13 (after the 48 h post -final dose sample time point) with instr uctions to return 
fasted on the mornings of Day 14 for 72 h PK sample, Day 15 for 96 h PK sample, and Day 16 for 120 h PK sample.
2017N322544_01 CONFIDENTIA L
205820
193. INTRODUCTION
3.1. Stud y Rationale
This will be a two- part study  design that will confirm the acceptability /selection of a 
tablet fo rmulation for future clinical development of GSK2838232.
Part 1 is a relative bioavailability  study  that will assess single RTV -boosted doses of a 
novel tablet formulation given with food (normal, approximately 30% fat) against the 
reference capsule formul ation also given with food (Part 1A) and then will assess the 
impact of fasted conditions on the tablet performance (Part 1B).
Part 2 is a study  of non -boosted GSK2838232, given as once- daily tablet doses for 
11days in a separate cohort of participants, a ssuming the tablet performance is 
considered acceptable from Part 1A.  The dose of GSK2838232 used in Part 2 will be 
confirmed after Part 1A but is likely  to be, and will not exceed, 500 mg QD as tablets.  
3.2. Background
Human immunodeficiency virus (HIV) inf ection affects approximately  37 million people 
worldwide [ UNAIDS Fact Sheet, 2015 ].  While antiretroviral (ARV) therapy  has been 
tremendously  successful over the past 20 y ears in reducing morbidity  and mortality , there 
continues to b e a medical need given viral resistance to existing drug classes and acute 
and chronic drug toxicities.  New drug classes targeting novel viral replication 
mechanisms would overcome HIV resistance to existing ARV drugs and may improve 
long-term safet y by r eplacing older agents with known safet y liabilities.
Maturation inhibitors represent a new class of compound for the treatment of HIV 
infection, distinct from viral entry , protease, reverse transcriptase or integrase inhibitors 
[Qian , 2009].  GSK2838232 is a maturation inhibitor being developed for the treatment 
of human HIV -
1.
An extensive preclinical package of work has been completed, including biology / 
virology , safet y assessment (toxicology), and preclinical PKstudies.  GSK2838232 has 
also been administered to 124 healthy  non- HIV-infected human participants in four 
clinical studies completed so far across a number of single and repeated dose designs, 
utilizing earl y clinical formulations.  The PK, safety , and tolerability profile o btained so 
far supports continued clinical development of GSK2838232, and there is an ongoing 
study  in HIV -infected patients that was initiated in the United States (US) in 1Q2017.  
There is a need to transition to a more suitable tablet formulation, which is one of the 
major objectives of this study .
3.2.1. Pharmacokinetic Summary
The original formulation used in the first three studies with GSK2838232 (HMI 116787, 
200207, and 200912) was Spray Dried Dispersion (SDD).  Data from Study  200912 
demonstrated that a ch ange to the active pharmaceutical ingredient (API) formulation of 
2017N322544_01 CONFIDENTIA L
205820
20GSK2838232 was feasible for future clinical studies.  Study  204953 utilized micronized 
API powder in a bottle as well as in a capsule.
GSK2838232 SDD did not overall demonstrate significant escalation in 
exposure from an increase in dose from 100 mg to 200 mg in a cross- study  
comparison.  The API powder in bottle ( PiB)formulation showed a 
proportional increase in AUC and Cmax for a 2- fold dose escalation from 
100mg to 200 mg.
The observed t max of the API  form was significantly  increased over the SDD 
formulation (the API formulation also increased tlag relative to SDD).
The bioavailability  of the GSK2838232 API  formulation was on average 
30to50% of the bioavailability  of SDD formulation, bu t there was a large 
observed range of relative intra-subject exposures (11 to 150%).
Both 10 mg SDD and 20 mg API showed a 10- fold or greater increase in AUC 
with steady -state RTV (100 mg QD for 10 day s) with a smaller ( ≤ 4-fold) 
increase in observed Cmax.  The t½ of GSK2838232 increased from 
15to18
hours to 34 to42 hours in the presenc e of stead y-state RTV, 
regardless of formulation.
After single doses of 50 mg to 250 mg GSK2838232 with RTV, increases in 
maximum observed concentration (Cmax )and area under the concentration -
time curve from time zero (pre -dose) extrapolated to infinite time (AUC [0-]) 
values were broadl y proportional to the increase in dose.  On Day  11 after 
repeated dail y 20 mg to 200 mg doses of GSK2838232 with RTV, increases in 
Cmax and area under the curve (Area under the plasma drug concentration -
time curve from pre -dose to the end of the dosing interval at steady  state) 
(AUC [
0-]) values appeared to be proportional to the increase in dose with the 
PiB and capsule formulations.
The relative bioavailability  of the micronized API  powder blend in capsules 
with RTV was ap
proximately  45% to 60% higher than the bioavailability  of 
the micronized API  administered as oral suspension from PiB with RTV.
Co-administration of the micronized API  powder blend in capsules with RTV 
and a normal fat meal resulted in an approximately  60% increase in geometric 
mean Cmax and AUC(0 -) values compared to the fasted state with RTV.
Variability  remains fairly constant across formulations and boosted versus unboosted at 
around 30% to 40% (moderate -high).
Full details of non -clinical and clinical data may  be found in the current Investigator’s 
Brochure (IB) [ GlaxoSmithKline ( GSK )Document Number 2012N151889_03].
2017N322544_01 CONFIDENTIA L
205820
213.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reaso nably expected adverse eve nts of GSK2838232 m ay be found in the Investigator ’s 
Brochure.   The following section outlines the risk assessment and mitigation strategy  for 
this protocol:
2017N3 22544_01 CONFIDENTIA L
205820
223.3.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Dat a/Rationale for Risk Mitigation Strategy
Investigational Product (IP) GSK2838232
Cardiovascular Pre-clinical studies have shown the following 
findings: elevated heart rates, an isolated episode of 
non-sustained ventricular tachy cardia and minimal to 
mild, sporadic troponin I  elevations in dogs.  A 
subsequent investigative cardiovascular stud y in 
telemetered dogs treated for four weeks did not 
replicate these effects.  Isolated microscopic 
cardiovascular changes were noted (focal extramural 
arteritis and l ocalized epicardial inflammation), 
however these changes were considered of uncertain 
relationship to GSK2838232 because similar findings 
occur at low incidence in normal beagles and there 
were no GSK2838232
-related functional changes by  
telemetry  and echo cardiography , or changes in cTpnI  
and NTproBNP.  In addition, there was no correlation 
between histologic changes and plasma exposure or 
heart tissue concentrations of GSK2838232. 
Toxicology  studies in rat and dog (3, 6 and 9 months) 
did not demonstrate a ny evidence of cardiovascular 
injury  or impact on cardiovascular function.
In the four GSK2838232 studies conducted so far, 
there was no pattern of cardiovascular changes of 
clinical significance related to GSK2838232 and no Participants will be clinically monitored for 
any signs of m yocardial injury  (chest pain, 
short ness of breath, pain with inspiration), 
elevated heart rate or arrhythmias.  Samples 
for the assessment of troponin will be taken.  
Baseline ECG and Holter (to use for 
screening and for later comparisons if 
needed)
Exposures of GSK2838232 will be closely  
monitored in the clinical study  so as to not 
exceed PK stopping criteria.
2017N3 22544_01 CONFIDENTIA L
205820
23Potential Risk of Clinical 
SignificanceSummary of Dat a/Rationale for Risk Mitigation Strategy
clinically  significant abnormal ity in electrocardiogram 
(ECG) values other than the two serious adverse 
events (SAEs) documented and discussed.
Review of published bevirimat preclinical and clinical 
safet y data indicates no significant toxicities or 
adverse events (AEs) of interest, oth er than a 30% 
incidence of gastrointestinal sy mptoms (including 
diarrhea).  There were no significant cardiovascular 
AEs reported in published clinical studies.
Hepatic In dogs given 70 mg/kg/day  for 9 months, there were 
reversible liver changes consisting of pigment 
accumulation (presumed bile) associated in some 
individuals with modest inflammatory  cell infiltration 
and isolated serum alanine aminotransferase activity  
(ALT) elevations.  Adverse effects in the liver were 
limited to one species and manifested onl y after 
prolonged dosing with no apparent effect on the 
clinical health of the a nimals; the effects were of 
modest severity
 and reversible, and the potential for 
such effects in human participants can be monitored in 
clinical studies.
In stud y 200912, a 47 -year-old female who received a 
dose of GSK2838232 20 mg and 9 day s of RTV 
100mg, developed abdominal pain, nausea, flatulence 
with grade 4 elevations in AL T/ aspartate 
aminotransferase (AST) and grade 2 elevations in total 
bilirubin.  A liver ultrasound revealed a dilated Persons with underly ing liver or biliary  
disease or abnormalities in liver function 
tests will be excluded from study  
participation.  Participants will be closely  
monitored for s ymptoms and signs of liver 
dysfunction, including serial monitoring of 
liver enzy mes and chemistries.
Use of concomitant 
medications/supplements and intake of 
alcohol is not allowed during the stud y.
Exposures of GSK2838232 will be closely  
monitored in the clinical study  so as to not 
exceed PK stopping criteria.
The stud y has pre -defined liver stopping 
criteria.
2017N3 22544_01 CONFIDENTIA L
205820
24Potential Risk of Clinical 
SignificanceSummary of Dat a/Rationale for Risk Mitigation Strategy
common bile duct and gallstones.  An endoscopic 
retrograde c holangio- pancreatograph y (ERCP) 
showed a dilated common bile duct with no filling 
defect.  She was diagnosed with a common bile duct 
obstruction due to gallstones that spontaneously  
resolved.  The Investigator considered this liver event 
as unrelated to st udy drug.
Ritonavir (RTV)
General The most frequentl y reported adverse drug reactions 
among patients receiving RTV were gastrointestinal 
(including diarrhea, nausea, vomiting, abdominal pain 
[upper and lower]), neurologic al disturbances 
(including paresthesia and oral paresthesia), rash, and 
fatigue/asthenia.Participants will be closely  monitored for 
any symptoms potentially  associated with 
RTV administration.
Cardiovascular The RTV label includes the following cardiovas cular 
AEs (which occurred in less than 2% of adult patients 
receiving RTV in all phase II/phase III studies and 
considered at least possibly  related or of unknown 
relationship to treatment and of at least moderate 
intensity ):cardiovascular disorder, cereb ral ischemia, 
cerebral venous thrombosis, hy pertension, 
hypotension, migraine, my ocardial infarct, palpitation, 
peripheral vascular disorder, phlebitis, postural 
hypotension, tach ycardia and vasospasm.  During 
post-marketing use of RTV first- degree AV bloc k, 
second -degree AV block, third -degree AV block, right Participants will be closely  monitored for 
any symptoms potentially  associated with 
RTV administration.  Specificall y, 
participant s will be clinically  monitored for 
any signs of m yocardial injury  (chest pain, 
shortness of breath, pain with inspiration, 
cardiac troponin I [cTnI], ECG changes), 
elevated heart rate or arrhy thmias.  S erial 
ECGs will be used at each treatment period 
on-study .
2017N3 22544_01 CONFIDENTIA L
205820
25Potential Risk of Clinical 
SignificanceSummary of Dat a/Rationale for Risk Mitigation Strategy
bundle branch block have been reported .
Hepatitis Hepatic transa minase elevations > 5x the upper limit 
of normal, clinical hepatitis, jaundice, and hepatic 
dysfunction (including fatalities) have occurred in 
patients receiving RTV alone or in combination with 
other antiretroviral drugs.  There may  be an increased 
risk for transaminase elevations in patients with 
underly ing hepatitis, pre -existing liver diseases, or 
liver enzy me abnormalities, and in patients taking 
multiple concomitant medications and/or with 
advanced acquired immunodeficiency  syndrome 
(AIDS).Enrolmen t into the study  will be limited to 
healthy  volunteers who do not have not 
underly ing liver disease, hepatitis or liver 
enzy me abnormalities.  Liver enzy mes 
(ALT, AST, total and direct bilirubin, 
alkaline phosphatase) will be determined at 
screening and mo nitored throughout the 
study  period.
Pancreatitis Pancreatitis has been observed in patients receiving 
RTV therap y, and in some cases fatalities have been 
observed.Participants will be closely  monitored for 
any symptoms of pancreatitis, including 
nausea, vomiting, abdominal pain and 
anorexia.  L ipase will be monitored 
throughout the treatment period.
2017N3 22544_01 CONFIDENTIA L
205820
26Potential Risk of Clinical 
SignificanceSummary of Dat a/Rationale for Risk Mitigation Strategy
Adverse Drug Reactions due to 
Drug InteractionsInitiation of RTV, a cytochrome P ( CYP ) 3A inhibitor, 
in patients receiving medications metabolized by  
CYP3A or initiation of medications metabolized by 
CYP3A in patients already  receiving RTV, may  
increase plasma concentrations of medications 
metabolized by  CYP3A.  I nitiation of medications that 
inhibit or induce CYP3A may  increase or decrease 
concentrations of RTV, respectivel y.  These 
interactions may lead to clinically  significant adverse 
reactions, potentiall y leading to severe, life -
threatening, or fatal events from greater exposures of 
concomitant medications, or clinically  significant 
adverse reactions fr om greater exposures of RTV Use of concomitant medications (besides 
GSK2838232), herbals and dietary  
supplements is exclusionary  and will be 
prohibited.  Participants will also be 
instructed to avoid ingestion of grapefruit 
juice.
2017N322544_01 CONFIDENTIA L
205820
273.3.2. Benefit A ssessment
This is a study  in health y participants and as such there is no expected benefit to the 
participants that will receive GSK2838232.  Participation in this study  may  contribute to 
the process of developing new therapies for HIV.  There may  be benefit to individ ual 
participants from the medical evaluations and assessments that could identify conditions 
to which the participant was previousl y unaware.
3.3.3. Overall Benefit: Risk Conclusion
GSK2838232, with its novel mechanism of action, can potentiall y provide benefit t o 
HIV-1 infected patients experiencing virologic failure due to multi -drug resistant virus or 
those with intolerance to other antiretroviral therapies.  Given the preclinical profile and 
the clinical profile to date, the overall risk to healthy  participant s at the proposed 
GSK2838232 doses (with or without RTV) is predicted to be low.
While cardiovascular -related events have been observed, the totalit y of the pre -clinical 
and clinical data suggest a low likelihood of cardiac toxicity  from GSK2838232.  
Never theless, there will be close monitoring of cardiovascular (CV) parameters, as 
described below, and CV -related stud y stopping criteria will be implemented to further 
reduce the potential risk to participants.
In addition, the 9 -month dog toxicity  study  identified adverse liver findings that were 
mild, reversible, can be monitored, and only occurred after prolonged exposure to 
concentrations that are greater than the average exposure expected from the highest dose 
level in this study .  To diminish the potenti al risk of liver toxicity , persons with 
underly ing hepatic or biliary  abnormalities will be excluded, liver enzy mes will be 
closely  monitored, and liver -stopping criteria will be implemented in this study .
Participants will also be at risk for AEs from RTV use (Part 1 onl y) and will be 
monitored closely  for such events.
Projected exposure and Ctrough values for the proposed doses of GSK2838232 indicate a 
high likelihood of attaining concentrations that will afford significant anti -viral benefit to 
HIV-infec ted patients but will be below the no AE dose level (NOAEL) seen in 
preclinical studies.  Therefore ,the risks in this study  are considered justified based on 
benefits that may  be afforded to participants with HIV infection.
2017N322544_01 CONFIDENTIA L
205820
284. OBJECTIVES A ND ENDPOINTS
Part 1 :
Objectives Endpoints
Primary
To assess the relative 
bioavailability  of a novel 
GSK2838232 tablet 
formulations versus the capsule 
formulation (Part 1A)AUC(0 -) and Cmax,
To assess the effect of food on 
GSK2838232 exposure of the 
tablet formulation (Pa rt 1A and 
Part 1B)AUC(0 -), Cmax, and tmax
Secondary
To investigate the safety  and 
tolerability  of GSK2838232 
following single dose 
administration as tablets or 
capsules, with RTVGSK2838232 safet y parameters: AEs; 
absolute values and changes over time 
of clinical laboratory  evaluations 
(hematology , clinical chemistry , 
urinaly sis), vital signs, and ECG 
parameters from pre -dose values
To characterize the PK of 
GSK2838232 after 
administration of a novel tablet 
formulation and capsule 
formulation with food , and the 
tablet formulation given without 
foodtlag, tmax, t½, tlast, C24, and 
AUC(0 -t)
Part 2:
Objectives Endpoints
Primary
To assess the safet y of 
GSK2838232 administered as 
non-boosted once -daily  doses of 
a tablet formulation for 11 day sGSK2838232 safet y parameters: AEs; 
absolute values and changes over time 
of clinical laboratory  evaluations 
(hematology , clinical chemistry , 
urinaly sis), vital signs, and ECG 
parameters from pre -dose values
To assess the PK of 
GSK2838232 administered as 
non-boosted once -daily  doses of 
a tablet formulation for 11 day sDay 1 dose: AUC(0- ), Cmax, C , 
tmax, tlag
Day 11 dose: AUC(0- ), AUC(0 -), 
Cmax, C , tmax, t½, tlast
2017N322544_01 CONFIDENTIA L
205820
29Objectives Endpoints
Secondary
To assess time to stead y-state of 
GSK2838232 when 
administered as non -boosted 
once -dailydoses of a tablet 
formulation for 11 day sPre-dose concentrations on Day s 2 
to11
To assess accumulation of 
GSK2838232 when 
administered as non -boosted 
once -daily doses of a tablet 
formulation for 11 day sAccumulation ratios: Ro[AUC(0- )], 
R(Cmax), R(C )
t1/2= Apparent terminal phase half -life; tmax= Time of occurrence of Cmax; tlag= Lag-time (time delay between drug 
administration and first observed concentration above LOQ in plasma); AUC (0 -t) = Area under the concentration -time 
curve from zero up to a definite time t
5. STUDY DESIGN
5.1. Overall Design
This study  is divided into two study  parts, Part 1 ( Figure 1) and Part 2 ( Figure 2).
Part 1:
Figure 1 Part 1: Single Dose, Food E ffect Study  Design Schematic
Part 1 is a relative bioavailability  study  (Table 4) that will further subdivide into 
two parts (Part 1A and Part 1B).
In Part 1A, the safet y and PKof a novel tablet formulation of GSK2838232 will 
be evaluated in open label, randomized, cross -over fashion against the capsule 
formulation as reference.
2017N322544_01 CONFIDENTIA L
205820
30Each actual treatment dose will be separated by a minimum 10 -day washout 
period.  Part 1A will be studied in the fed state using a normal fat (i.e., 
approximately  30%) meal in all participants.
The safet y and PKwill be evaluated, and the tablet will be evaluated for 
suitability , and further clinical assessment in Part 1B, where the tablet will be 
administered in the fasted state to understand the impact of food on relative 
bioavailability .
GSK2838232 as tablets or capsules (at a 200 mg dose level) will be administered 
with 100 mg RTV, after two pre -doses of 100 mg RTV QD over 48 h.  The use of 
RTV priming is an aspect of GSK2838232 clinical development (s pecifically  
relative bioavailabilit y studies) so far and allows a more accurate assessment of 
what will ultimately  happen in the repeat -dose clinical studies with GSK2838232 
when boosted with RTV.  I n Part 2 of the study , however, GSK2838232 will be 
admini stered unboosted and no RTV will be co administered.
Participants will have a screening visit within 30 day s prior to first dose, a 
minimum 10 -day washout period between doses, and a follow- up visit 7 to 14 
days after the last dose.  The maximum duration o f study  participation will be 
approximately  9to 10 weeks.
Table 4 Study  Design for Part 1
SequenceN Part 1A Part 1B
Period 1 Period 2 Period 3
1 6 A B C
2 6 B A
1.All treatments in Part 1A to be administered w ith RTV in fed s tate, following two RTV pre -doses.
2.There w ill be a w ashout of at least 10 days between each Period.
3.Treatment A = GSK2838232 200 mg/r (as 4 x 50 mg) capsule formulation, fed, normal fat (i.e., 
approximately 30%) meal (reference).
4.Treatment B = GSK2838232 2 00mg/r (as 2 x 100 mg) tablet formulation, fed, normal fat (i.e., 
approximately 30%) meal.
5.Treatment C = GSK2838232 200 mg/r (as 2 x 100 mg) tablet, confirmed from Part 1A, fasted.
After completion of Part 1A, preliminary  PK data will be anal yzed, and a decision will be 
made based on tolerability, relative bioavailabilit y PK criteria, as well as feasibility  
considerations, as to whether the tablet formulation will be used to conduct Part 1B 
(fasted) and Part 2.
2017N322544_01 CONFIDENTIA L
205820
31Part 2:
Figure 2 Single Daily  Dose Study  Design Schematic
Part 2 will evaluate non -RTV boosted GSK2838232, given as single daily  doses 
for 11 days in a separate cohort of participants (N=8; 6A/2P).
The placebo tablet supplied will not be identical to GSK2838232 and as such will 
be administered b y site staff via an opaque card/paper tube to facilitate the single 
blind (i.e., the Principal Investigator [ PI]and the participants themselves will be 
blinded as to their treatment).
The dose chosen for Part 2 will depend upon the preliminary  results of the tablet 
in Part 1A but is likely  to be, but will not exceed, 500 mg (i.e., 5 x 100 mg tablets) 
QD.  
Participants will have a screening visit within 30 day s prior to first dose, and a 
follow -up visit 7 to 14 day s after the last dose.  The maximum duration of study  
participation will be approximately  8 to 9 weeks.
Study Population:
The study  population will consist of healthy  male or female participants (women of child 
bearing potential [WOCBP] are permitted as long as the crit eria for contraception are 
adhered to), as per inclusion/exclusion criteria (Section 6).
Note: Participants in both Part 1 and Part 2 will have a 24 -
h Holter screen as part of 
baseline evaluation.  Holter monitoring may  appl y during the stud y period if needed.
Study Plan:
Because of the requirement to begin RTV pre -dosing 48 hours before each treatment dose 
in Parts 1A and 1B, participants will be admitted to the Clinical Unit three nights before 
each of the treatment periods an d remain in the Unit until the last (120 h) PK time -point 
of each treatment period is collected.  There is no such earl y admission requirement for 
Part2 (non
-boosted GSK2838232).
2017N322544_01 CONFIDENTIA L
205820
32If participants prematurely discontinue the stud y, additional participants may be 
randomized and assigned to the same treatment sequence at the discretion of the Sponsor 
in consultation with the Investigator .
5.2. Number of Participants
In order to have sufficient evaluable participants for the above mentioned study  
objectives, it is e xpected that a sufficient number of participants will be screened in order 
to enroll a sufficient number of participants for analysis as given below:
Part 1:
It is expected that approximately  16healthy  participants will be enrolled to provide at 
least 12 evaluable participants through the three study  periods (at least 6 participants per 
treatment).  Participants will be evenl y assigned to one of the two treatment sequences for 
the crossover design Part 1A.
Part 2:
It is expected that 10 healthy  participant s will be enrolled to provide at least 8 evaluable 
participants through the single stud y period.
5.3. Participant and Study  Completion
A completed participant is one who has received the study  treatment per the protocol and 
who has completed all phases of the s tudy including the follow -up visit.
The end of the stud y is defined as the last participant’s last visit.
5.4. Scientific Rationale for Study  Design
Study  HMI116787 was the First Time in Human (FTiH) clinical trial of GSK2838232 
and assessed the safet y and tole rability  of escalating doses (5 mg to 100 mg), food effect 
and the impact of stead y
-state RTV on GSK2838232 PK.  The study was completed in 
November 2013, and safety  and PK data warranted continued investigation of 
GSK2838232.
Subsequent clinical studies 200912 and 200207 were carried out in healthy participants 
and extended the dose range studied as follows:
Study  200207: Repeated doses of GSK2838232 SDD alone (20 mg and then 
50mg QD for 8 day s), and then with RTV as 10 mg SDD GSK2838232 + RTV 
QD for 5 da ys.
Study  200912 : Dosed up to 200 mg GSK2838232 alone as single doses (as either 
SDD or API PiB) or 20 mg GSK2838232 API PiB single dose with stead y-state 
RTV.
Study  204953 has completed the clinical phase in 4Q2016 and was a double -blind 
(except for the r elative bioavailability  cohort, Part 1B), placebo -controlled, single 
2017N322544_01 CONFIDENTIA L
205820
33(Part 1A; dose levels of 50 to 250 mg ) followed b y a repeat dose (Part 2 ; dose levels of 
20 to 200 mg QD ) escalation study  to investigate the safet y, tolerability  and PK of 
GSK2838232 as API, co -dosed with RTV 100 mg QD.  GSK2838232 was administered 
without RTV in the last cohort of repeat dosing to assess achievable plasma 
concentrations with unboosted GSK2838232 (200 mg twice daily  [BID]).
This study  then completes the assessment of clin ical trial formulation (tablets) for 
Phase IIb and III as well as an assessment of higher QD doses of GSK2838232 
unboosted.
5.5. Dose Justification
The dose for Part 1A and Part 1B of this study  will be 200 mg (ach ieved as either 
4 x 50 mg capsules or 2 x 100 m g tablets) administered with 100 mg RTV.  This dose 
level was tested in Study  204953 and provides a suitable PK profile for assessment of 
formulation performance.
The dose for Part 2 will be confirmed from Part 1A but is likely  to be, and will not 
exceed, 500 mg (as 5 x 100 mg tablets).  The dose of 500 mg is justified on the grounds 
that the utility  of non -boosted GSK2838232 in a QD regimen may  now be an achievable 
goal.  GSK2838232 has been previously assessed in repeated doses of i) 200 mg 
GSK2838232 QD in combination with 100 mg RTV QD for 11 day s, and ii) non- boosted 
200mg GSK2838232 BID for 11 day s (Study  204953).  This study  will assess the 
highest practical once -daily  dose of GSK2838232.
6. STUDY POPULA TION
Specific information regarding warnings, prec autions, contraindications, AEs and other 
pertinent information on the GSK I P or other study  treatment that may  impact participant 
eligibility  is provided in the IB .
Deviations from inclusion and exclusion criteria are not allowed because they could 
potent ially jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
participant safety.  Therefore, adherence to the criteria as specified in the protocol is 
essential.
2017N322544_01 CONFIDENTIA L
205820
346.1. Inclusion Criteria
A participant will be eligible for inclusion in this study  only if all of the following criteria 
apply :
AGE
1.Between 18 and 55 years of age inclusive, at the time of signing the informed 
consent.
TYPE OF PARTICI PANT AND DIAGNOSIS INCL UDING DI SEASE SEVERI TY 
2.Health y as determined by the Investigator or med ically  qualified designee based 
on a medical evaluation including medical history , phy sical examination, 
laboratory  tests and cardiac monitoring.
3.A participant with a clinical abnormalit y or laboratory parameter(s) which is/are 
not specificall y listed in t he inclusion or exclusion criteria, and outside the 
reference range for the population being studied, may  be included onl y if the 
Investigator in consultation with the Medical Monitor, if required, agree and 
document that the finding is unlikely  to introdu ce additional risk factors and will 
not interfere with the study  procedures.
4.A creatinine clearance > 80mL/min as determined by  Cockcroft- Gault equation:
CLcr (mL /min) = (140 –age) * Wt / (72 * Scr) (times 0.85 if female) where age is 
in years, weight (W t) is in kg, and serum creatinine (Scr) is in units of mg/dL.
WEI GHT
5.Body weight 50.0 kg (110 lbs.) for men and 45.0 kg (99 lbs) for women and 
body  mass index (BMI) within the range 18.5 to 31.0 kg/m2(inclusive).
SEX
6.Males or females
A female parti cipant is eligible to participate if she is not pregnant (as confirmed 
by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, 
and of non- reproductive potential which is defined as:
Reproductive potential:
There is no definitive drug -drug interaction (DDI) information with GSK2838232 
and an interaction with oral contraceptives is pos sible, so other (barrier, 
2017N322544_01 CONFIDENTIA L
205820
35inter-uterine device etc.) methods of contraception will be required.
Females of reproductive potential may  only be enrolled if t hey are using two 
forms of complementary  contraception, which must include at least one barrier 
method.  They  will be counselled on safer sex practices.
Fertile females, who have an established, long -term lifesty le of sexual abstinence, 
or only  same sex pa rtners, require no other means of birth control.
Non-reproductive potential:
Pre-menopausal females with one of the following:
Documented tubal ligation,
Documented hysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occl usion,
Hysterectom y,
Documented Bilateral Oophorectom y.
Postmenopausal defined as 12 months of spontaneous amenorrhea in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause ( refer to 
laboratory  reference ranges for confirmatory  levels).  Females on hormone 
replacement therap y (HRT) must discontinue HRT to allow confirmation of 
post-menopausal status prior to study  enrolment.
Male participants with female partners of child bear ing potential must comply  
with the following contraception requirements from the time of first dose of study  
medication until one week after the last dose of study  medication.
a.Vasectom y with documentation of azoospermia.
b.Male condom plus partner use of one of the contraceptive options below:
Contraceptive subdermal implant that meets the Standard operating 
Procedure (SOP) effectiveness criteria including a <1% rate of failure per 
year, as stated in the product label,
Intrauterine device or intrauterine s ystem that meets the SOP effectiveness 
criteria including a <1% rate of failure per year, as stated in the product 
label,
Oral contraceptive , either combined or progestogen alone or Injectable 
progestogen,
Contraceptive vaginal ring,
Percutaneous contraceptiv e patches.

These allowed methods of contraception are only  effective when used 
2017N322544_01 CONFIDENTIA L
205820
36consistently , correctly  and in accordanc e with the product label.  The Investigator
is responsible for ensuring that participants understand how to properl y use these 
methods of contraception.
INFORMED CONSENT
7. Capable of giving signed informed consent, which includes compliance with the 
requirements and restrictions listed in the consent form and in this protocol.
6.2. Exclusion Criteria
A participant will not be eligible for in clusion in this study  if any  of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1.Alanine transaminase (ALT) >1.5x upper limit of normal (ULN) 
2.Bilirubin >1.5xUL N (isolated bilirubin >1.5xULN i s acceptable if bilirubin is 
fractionated and direct bilirubin <35%). 
3.Current or chronic history of liver disease, or known hepatic or biliary  
abnormalities.
4.Participants who have asthma or a history  of asthma.
5.Medical history  of cardiac arrhy thmias or ca rdiac disease or a famil y orpersonal 
history  of long QT s yndrome.
CONCOMI TANT MEDICATIONS
6. Unable to refrain from the use of prescription or non- prescription drugs, including 
vitamins, herbal and dietary  supplements (including St John’s Wort) within 7 days 
(or 14 days if the drug is a potential enzy me inducer) or 5 half-lives (whichever is 
longer) prior to the first dose of study  medication, unless in the opinion of the 
Investigator and GSK Medical Monitor, the medication will not interfere with the 
study procedures or compromise participant safety .
REL EVANT HABITS
7.History  of regular alcohol consumption (within 6 months prior to screening or 
unable to refrain from alcohol use from 5 day s prior to admission through the last 
blood sample collected) defined as:
For US sites: an average weekl y intake of >14 drinks for males or >7 drinks 
2017N322544_01 CONFIDENTIA L
205820
37for females.  One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) 
of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof 
distilled spirits.
8.Regular us e of tobacco - or nicotine- containing products within 6 months prior to 
screening.  Unable to refrain from smoking from the Screening Visit through the 
last blood sample collected.  As confirmed b y a urine cotinine test.
CONTRAINDICAT IONS
9.History  of sens itivity  to any  of the stud y medications, or components thereof or a 
history  of drug or other allergy  that, in the opinion of the Investigator or Medical 
Monitor, contraindicates their participation.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
10.Presence of h epatitis B surface antigen (HBsAg), or positive hepatitis C virus 
(HCV) test result at screening or within 3 months prior to first dose of study 
treatment.
11. Screening or baseline cardiac troponin I greater than the 99% cutoff (>0.045ng/ml 
by the Dimension V ista cTnI  assay ) for a given assay .
12.A positive pre -study  drug/alcohol screen.
13.A positive test for HIV antibody .
14.Where participation in the study  would result in donation of blood or blood 
products in excess of 500 mL within 56 day s.
15.The participant has par ticipated in a clinical trial and has received an 
investigational product within the following time period prior to the first dosing 
day in the current study : 30 day s, 5 half -lives or twice the duration of the 
biological effect of the investigational product (whichever is longer).
16. Exposure to more than four new chemical entities within 12 months prior to the 
first dosing day .
17. Exclusion Criteria for 24- hour Screening Holter:
Any symptomatic arrhy thmia (except isolated extra s ystoles).
Sustained cardiac arrh ythmias (such as atrial fibrillation or flutter, 
supraventricular tach ycardia ( 10 consecutive beats), complete heart block).
Non-sustained or sustained ventricular tach ycardia (defined as 3 
consecutive ventricular ectopic beats).
Any conduction abnormal ity (including but not specific to left or right 
incomplete or complete bundle branch block, atrioventricular (AV) block 
[2nd degree or higher], Wolf fParkinson White (WPW) sy ndrome etc.).
2017N322544_01 CONFIDENTIA L
205820
38Sinus Pauses >3 seconds.
300 or more supraventricular ectopic beats in 24 hours.
250 or more ventricular ectopic beats in 24 hours.
18.Any clinically  significant abnormal echocardiogram finding (should be discussed 
with the Medical Monitor prior to enrolment).
19.Exclusion criteria for screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 or >100 bpm <50 or >100 bpm
PR Interval <120 or > 220msec
QRS duration <70 or >120 msec
QTc interval (Fridericia’s) >450 msec
Note: A heart rate from 100 to 110 bpm can be rechecked by EC G or vitals 
within 30 minutes to verify eligibility.
Evidence of previous m yocardial infarction (does not include ST segment 
changes associated with re-polarization).
Any conduction abnormality  (including but not specific to left or right 
complete bundle b ranch block, AV block [2nd degree or higher], WPW 
syndrome).
Sinus Pauses >3 seconds.
Any significant arrh ythmia which, in the opinion of the Investigator OR GSK 
Medical monitor, will interfere with the safet y for the individual participant.
Non-sustained or sustained ventricular tach ycardia ( 3 consecutive 
ventricular ectopic beats).
6.3. Lifest yle Restrictions
6.3.1. Meals and Dietary  Restrictions
Participants should avoid consumption of red wine, Seville oranges, grapefruit or 
grapefruit juice (and/or pomelos, exo tic citrus fruits, grapefruit hybrids or fruit juices) 
from 5 day s before the first dose of study  medication, until follow -up.
Participants should refrain from eating popp y seed -containing food (e.g., poppy  cake) at 
least 3 day s before admission as this ca n falsify  the urine drug screen.  A positive illicit 
drug result will lead to exclusion from the remainder of the stud y.
Water is allowed ad libitum throughout the stud y.
2017N322544_01 CONFIDENTIA L
205820
39While in residence in the clinical research unit (admission through discharge), 
participants will be restricted to food and beverage that is site -provided at specific 
times.  Participants are expected to complete all meals and snacks (100%) within 25 
minutes (Parts 1A and Part 1B).  Non -compliance will be recorded.
Participants will be fed a “normal” standardized diet consisting of an average 
between 3400 to 4000 kcal for each full day  in residence (with the exception of Part 
1B dosing day s where dosing is conducted under fasted conditions).  A 5% variance 
in calories is allowed.  The macro nutrient distributions and caloric criteria are within 
the recommendations in the Dietary Guidelines for Americans , 2010.
Part 1A and Part 2
Standardized meals will be provided to participants in Part 1A start ing with Day 1 
through discharge from the clinical research unit.
Standardized meals and snacks should be completed within 25 minutes.  Participants 
will be expected to complete all meals and snacks (100%).  Non -compliance on Day  
1 will be recorded in incr ements of 25% (e.g., 0%, 1
-25%, 26- 50%, 51 -75% or 76-
100% meal or snack completed).
Participants will undergo at least a 10 -hour overnight fast then will be provided a 
meal 30 minutes before dosing and will be expected to complete the meal within 25 
minute s.  Lunch will be provided approximately  4 hours after morning dosing and 
dinner will be provided approximately  9 hours after morning dosing.  On Day  1, all 
participants will receive identical meals at breakfast, lunch, dinner and snack.  On 
non-dosing day s, meals will be served per the standard times at the clinical research 
unit.
Part 1B (tablet, fasted):
Participants will undergo at least a 10 -
hour overnight fast prior to Part 1B 
GSK2838232 tablet dosing.  On the day  of dosing, participants will continue fasting 
after dosing (no breakfast).  L unch will be provided approximately  4 hours after 
morning dosing and dinner will be provided approximately  9hours after morning 
dosing.  On Day  1, all participants will receive identical meals at lunch, dinner and 
snack.  On non- dosing day s, meals will be served per the standard times at the 
clinical research unit.
6.3.2. Caffeine, A lcohol, and Tobacco
All enrolled participants will abstain from ingesting caffeine- or 
xanthine -containing products (e.g., coffee, tea, cola dr inks and chocolate) for 
48 hours before the start of dosing until collection of the final PK sample during 
each session.
All enrolled participants will abstain from red wine for 5 day s and other alcohol 
for 24 hours before the start of dosing until collection of the final PK sample 
during each session.
2017N322544_01 CONFIDENTIA L
205820
40Participants who currently use or have used tobacco products within 6 months of 
Screening will not be enrolled.
Participants must refrain from all illicit drugs throughout the stud y (from 
Screening until disc harge from the study ).  Drug screening will occur as indicated 
in the Schedule of Assessments ( Table 2 and Table 3) for each Part of the study .  
Participants should refrain from eating popp y seed -containi ng food (e.g., poppy  
cake) at least 3 day s before admission as this can falsify  the urine drug screen.  A 
positive illicit drug result will lead to exclusion from the remainder of the study .
6.3.3. Activity
Participants will abstain from strenuous exercise for 1 week before Admission and 
during the course of the study  and refrain from increasing their activity  above that 
which they  normall y perform.  Participants may participate in light recreational 
activities during studies (e.g., watch television, read).
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y randomized
. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participa nts to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities.  Minimal information includes 
demograph y, screen failure details, eligibility  criteria, and an y SAEs.
Indivi duals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened at the discretion of the PI.  Rescreened participants should be assigned 
the same participant number as for the initial screening.
7. TREATMENTS
The term ‘st udy treatment’ is used throughout the protocol to describe GSK2838232, 
RTV or the combination of the products received by  the participant as per the protocol 
design.
GSK2838232 will be supplied by  GSK as prefilled capsules or tablets in bulk for 
dispensing to participants at the site according to the treatment code.
Ritonavir –commercially  available; will be purchased/supplied either by  PAREXEL  or 
GSK.
7.1. Treatments A dministered
Details of the study  treatment are provided in 
Table 5below.
2017N322544_01 CONFIDENTIA L
205820
41Table 5 Investigational Product and Other Study  Treatment
Study Treatment Name: GSK2838232 NORVIR (ritonavir, 
RTV)Placebo (Part 2 only)
Dosage formulation: Tablets or Capsule Tablets *Tablet 
(non-matching) for 
the GSK2838232 
tablet formulation)
Unit dose 
strength(s)/Dosage 
level(s):200mg:
Capsules: 4 x 50 mg
Tablets: 2 x 100 mg100mg Not applicable
Route of Administration Oral Oral Oral
Dosing instructions: Part 1A: To b e 
taken with water 
and a meal (fed 
conditions)
Part 1B: To be 
taken with water 
after a fast (fasted 
conditions)
Part 2: To be taken 
with water and a 
meal once daily for 
11consecutive daysPart 1A: To be taken 
with water and a 
meal (fed conditions)
Part 1 B: To be taken 
with water after a fast 
(fasted conditions)Part 2: To be taken 
with water and a 
meal once daily for 
11 consecutive days
Packaging and Labeling GSK2838232 will be 
supplied by GSK as 
prefilled capsules or 
tablets in bulk for 
dispensing to 
participants at the 
site according to the 
treatment code.Placebo for 
GSK2838232 tablets 
will be provided, 
although are 
non-matching as 
tablets
Manufacturer/Source of 
procurement GSK Procured by 
PAREXELGSK
Physical Form Pink unmarked 
capsule
White to sl ightly 
colored tablet.White film -coated 
ovaloid tabletsWhite to slightly 
colored tablet.
2017N322544_01 CONFIDENTIA L
205820
42*The placebo (tablet) supplied w ill not be identical to GSK2838232 and as such will be administered by 
site staff via an opaque card/paper tube to facilitate the si ngle blind (i.e., the participant w ill be blinded as 
to their treatment).
The unblinded pharmacist or qualified designee will prepare GSK2838232 and placebo 
according to a pre -generated schedule of randomized treatment assignments.
7.1.1. Medical Devices
Not applicable.
7.2. Dose Modification
Not applicable.
7.3. Method of Treatment A ssignment
Participants will be assigned to study  treatment in accordance with the computer 
generated randomization schedule generated b y PAREXEL, using SAS version 9.3 or 
higher.  A separate r andomization schedule will be generated for each part of the study .  
At Screening, potential study  participants will be assigned a screening number.  
Participants will be randomized before the first dose of Study Drug in Part 1A 
(GSK2838232 tablet or capsu le, with RTV) or Part 2 (GSK2838232 tablet or placebo 
tablet, without RTV) after all screening assessments have been completed and after the 
Investigator has verified that they  are eligible per study  inclusion/exclusion criteria.  No 
participant may  begin treatment before randomization and assignment of a unique 
participant identification number.
Each participant scheduled to receive stud y treatment will receive a participant number 
when randomized.  The randomization number will determine the allocation of treatment 
sequences (ABC or BAC) for Part 1, and of treatment (GSK2838232 without RTV or 
placebo) for Part 2.  Allocation to treatment for Part 1A or Part 1B (with Part 2 being 
fixed) will be according to a predetermined random order.
7.4. Blinding
Part 1 of t he study  will be open label and thus not be blinded.
Part 2 of the study  will be single blinded because of the unavailability  of matching 
placebo tablets.  Certain site personnel preparing the treatment for administration will 
know what the treatment is bu t will administer the tablet or tablet placebo via an opaque 
tube/envelope to the participants.  The PI and the participants will be completely blinded 
to specific participant treatment assignment.
When possible, GSK/ contract research organization (CRO) personnel will not have 
access to participant- specific treatment assignment so as to not potentially  introduce bias 
in discussions with the study  center.
2017N322544_01 CONFIDENTIA L
205820
43The Investigator or treating phy sician may  unblind a participant’s treatment (Part 2 single 
blind) assi gnment only in the case of an emergency when knowledge of the study  
treatment is essential for the appropriate clinical management or welfare of the 
participant .  Whenever possible, the I nvestigator must first discuss options with the GSK 
Medical Monitor o r appropriate GSK study  personnel before unblinding the participant’s 
treatment assignment.  If this is impractical, the I nvestigator must notify  GSK as soon as 
possible, but without revealing the treatment assignment of the unblinded participant, 
unless t hat information is important for the safety  of participants currentl y in the study .  
The date and reason for the unblinding must be recorded in the appropriate data 
collection tool.
A participant will be withdrawn if the participant’s treatment code is unb linded by  the 
Investigator or treating physician.  The primary  reason for discontinuation (the event or 
condition which led to the unblinding) will be recorded in the data collection tool.
GSK’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  participant with an SAE.  If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the participant’s treatm ent assignment, may  be sent to Investigator s in 
accordance with local regulations and/or GSK policy.
7.5. Preparation/Handling/Storage/A ccountability
A description of the methods and materials required for preparation of GSK2838232, 
RTV or placebo will be detailed in a Technical Agreement. The formulations will be 
extemporaneously  prepared as per instructions that will be reviewed and approved by  
GSK before use.
1.The Investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
2.Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment.  All study  treatments 
must be stored in a secure, environmentall y controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the Investigator and authorized site staff.
3.The Investigator , institution, or th e head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final di sposition of unused study  treatment 
are provided in the Study Reference Manual.
5.Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .
6.A Material Safety  Data Sheet (MSDS)/equi valent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
2017N322544_01 CONFIDENTIA L
205820
44Investigator, where this is required b y local laws, or is available upon request from 
GSK.
7.6. Treatment Compliance
When the individual dose for a participant is prepared from a bulk supply , the 
preparation of the dose will be confirmed b y a second member of the stud y site staff.
When participants are dosed at the site, they  will receive study  treatment directl y 
from the Investigator or designee, under medical supervision.  The date and time of 
each dose administered in the clinic will be recorded in the source documents.  The 
dose of study  treatment and study  participant identification will be confirmed at the 
time of dosing b y a member of the study  site staff other than the person 
administering the stud y treatment.  Study  site personnel will examine each 
participant’s mouth to ensure that the study  treatment was ingested.
7.7. Concomitant Therapy
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the stud y must be recorded along with:
reason for use,
dates of administration including start and end dates,
dosag e information including dose and frequency .
The Medical Monitor should be contacted if there are an y questions regarding 
concomitant or prior therapy .
Participants must abstain from taking prescription or nonprescription drugs (including 
vitamins and dieta ry or herbal supplements) within 7 day s (or 14 day s if the drug is a 
potential enzy me inducer) or 5 half -lives (whichever is longer) before the start of study  
treatment until completion of the follow- up visit, unless, in the opinion of the Investigator
andsponsor, the medication will not interfere with the study .
Acetaminophen, at doses of 2g/day  is permitted for use an y time during the study .  
Other concomitant medication may  be considered on a case by  case basis by  the 
Investigator in consultation with the Medical Monitor.
7.8. Treatment after the End of the Study
Participants will not receive an y additional treatment from GSK after completion of the 
study  because onl y healthy participants are eligible for stud y participation.
2017N322544_01 CONFIDENTIA L
205820
458. DISCONTINUA TION CRITERIA
8.1. Disco ntinuation of Study  Treatment
8.1.1. Liver Chemistry Stopping Criteria
Study  treatment will be discontinued for a participant if liver chemistry stopping criteria 
are met:
Phase I Liver Chemistry Stopping Criteria – Liver Stopping Event Algorithm
Continue Study Treatment 
Discontinue Study Treatment  
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must  refer to Liver Safety Required Actions and Fol low up Asses sments  section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5 , if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Section 12.3, Appendix 3 .
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure participant safety  and e valuate liver event etiology  (in alignment with the Food 
and Drug Administration [FDA] premarketing clinical liver safety  guidance).  These 
protocol guidelines are in alignment with FDA premarketing clinical liver safet y 
guidance:
http://www.fda.gov/downlo ads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Discontinuation of study  treatment for abnormal liver tests should be considered by  the 
Investigator when a participant meets one of the conditions outlined in the algorithm 
above or if the Investigator believes that it is in the best interest of the participant.
2017N322544_01 CONFIDENTIA L
205820
468.1.2. QTc Stopping Criteria
The same QT correction formula must be used for each individual participant to 
determine eligibility  for and discontinuation from the study .  This form ula may  not 
be changed or substituted once the participant has been enrolled.
For example, if a participant is eligible for the protocol based on QTcF, then 
QTcF must be used for discontinuation of this individual participant as well.
Once the QT correctio n formula has been chosen for a participant’s eligibility , 
the same formula must continue to be used for that participant for all QTc data 
being collected for data analysis .  Safety  ECGs and other non -protocol specified 
ECGs are an exception.
A participant that meets the bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from study  treatment.
QTc, QTcB, QTcF >500 msec,
Change from baseline: QTcF >60 msec
8.1.3. Temporary  Discontinuation
Not applicable.
8.1.4. Rechallenge
Not applicable.
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the Investigator for safety , 
behavioral, compliance or administrative reasons.
If the participant w ithdraws consent for disclosure of future information, the 
sponsor may retain and continue to use any  data collected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples collected and not tested, and the Investigator must document this in the 
site study  records.
Refer to the Schedule of Assessments ( Table 2 and Table 3) for data to be 
collected at th e time of study  discontinuation and f ollow -up and for an y further 
evaluations that need to be completed.
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
2017N322544_01 CONFIDENTIA L
205820
47The fol lowing actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of ma intaining 
the assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study .
Before a participant is deemed lost to follow up, the Investigator or designee 
must make every  effort to regain contact with the participant (where possible, 
3telephone calls and, if necessary , a certified letter to the participant’s last 
known mailing address or local equivalent methods).  These contact attempts 
should be documented in the participant’s medical record.
Should t he participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Each participant will have adequate time to provide informed consent of his or her own 
free will and before conducting an y stud y procedures according to the International 
Conference on Harmonization (I CH) and Code of Federal Regulations (CFR) guidelines.  
Each participant will be provided a cop y of the signed informed consent docu ment (ICF) 
before the initiation of any stud y procedures.
After a participant has provided written informed consent and within 30 day s of the first 
dose of study  treatment, the Investigator or other study  personnel will determine if the 
participant is elig ible for enrolment in the study .  This will be done by  reviewing the 
inclusion and exclusion criteria and completing all of the screening assessments outlined 
in the Schedule of assessments Tables ( Table 2 and Table 3).  Screening assessments may  
be carried out over more than 1 day provided that all required assessments are completed 
within 30 day s before the first administration of study  treatment.
Protocol waivers or exemptions are not allowed with the e xception of immediate safety  
concerns.  Therefore, adherence to the stud y design requirements, including those 
specified in the Schedule of Assessments Tables ( Table 2 and Table 3), are essential and 
required for study  conduct.
Whenever vital signs, 12 -
lead ECGs and blood draws are scheduled for the same nominal 
time, the assessments should occur in the following order:
1. 12- lead ECG.
2.Vital signs.
3.Blood draws.
Note: The timing of the assessments should allow the blood draw to occur at the exact 
nominal time.  I n the event that the timing for a scheduled assessment conflicts with an 
2017N322544_01 CONFIDENTIA L
205820
48assessment that has to be repeated, the scheduled assessment will be performed on 
time/as scheduled and the repeat assessments wi ll be conducted when feasible.
The timing and number of planned study  assessments, including: safet y and PK 
assessments may  be altered during the course of the study  based on newl y available data 
(e.g., to obtain data closer to the time of peak plasma conc entrations) to ensure 
appropriate monitoring.
The Institutional Review Board (IRB) will be informed of an y safet y issues that require 
alteration of the safet y monitoring scheme or amendment of the Informed Consent Form.
The timing of planned study  assessme nts is listed in the Schedule of Assessments Tables 
(Table 2 and Table 3).
9.1. Efficacy  Assessments
Not applicable.
9.2. Adverse Events
The definitions of an AE or SAE can be found in Section 12.5, Appendix 5.
The Investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, consi dered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  treatment or study  (see Section 8).  
In addition, all ventricular tach yarrhythmias are considered AEs of interest and should be 
reported to the Sponsor within 24 hours.
9.2.1. Time Period and Frequency  for Collecting A dverse Event and 
Serious A dverse Event Information
All SAEs will be collected from the signing of the ICF until the follow
-up visit
at the time point s specified in the Schedule of A ssessments Tables ( Table 2and 
Table 3).
All AEs will be collected from the start of treatment until the follow -up visit at 
the time points specified in the Schedule of Ass essments Tables ( Table 
2and 
Table 3).
The Sponsor will inform FDA within 7 day s of any  grade 2 or higher “alteration 
in personality -behavior or in mood” or “altered mental status” adverse events 
that occ ur in participants who have received GSK2838232.
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the case report form (CRF
) not the AE section.
All SAEs will be recorded and reported to the sponsor or designee within 
24hours, as indicated in Section 12.5, Appendix 5.  The Investigator will submit 
any updated SAE data to the sponsor within 24 hours of it being available.
2017N322544_01 CONFIDENTIA L
205820
49Investigator s are not obligated to activel y seek AEs or SAEs in former study 
participants.  However, if the Investigator learns of any  SAE, including a death, 
at an y time after a participant has been discharge d from the study , and he/she 
considers the event to be reasonabl y related to the study  treatment or study  
participation, the Investigator must promptl y notify the sponsor.
NOTE: The method of recording, evaluating, and assessing causalit y of AEs and 
SAEs a nd the procedures for completing and transmitting SAE reports are 
provided in Section 12.5, Appendix 5.
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AEs and/or S AEs.  Open
-ended 
and nonleading verbal questioning of the participant is the preferred method to inquire 
about AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , 
since y our last visit/contact?” 
9.2.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the Investigator is required to proactivel y follow each 
participant at subsequent vi sits/contacts.  All SAEs and nonserious AEs of special interest 
(as defined in Section 3.3.1), will be followed until the event is resolved, stabilized, 
otherwise explained, or the participant is lost to follow -
up(as defined in Section 8.3).  
Further information on follow -up procedures is given in Section 12.5, Appendix 5.
9.2.4. Regulatory  Reporting Requirements for SA Es
Prom pt notification by  the Investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a study  treatment under clinical investigation are 
met.  In addition, all v entricular tach yarrh ythmias are considered AEs of interest 
and should be reported to the Sponsor within 24 hours.
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud ytreatment 
under clinical investigation.  The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
IRB/Independent Ethics Committees (I EC), and Investigator s.
Investigator safety  report
s must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory  requirements and 
sponsor policy  and forwarded to Investigator s as necessary .
An Investigator who receives an Investigator safety  report describing a SAE or 
other specific safet y information e.g., summary  or listing of SAE) from the 
2017N322544_01 CONFIDENTIA L
205820
50sponsor will review and then file it along with the Investigator ’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
Please see the SRM for SAE reporting contact details.
9.2.5. Pregnancy
Details of all pregnancie s in female participants and female partners of male 
participants will be collected after the start of study treatment and until the final 
follow -up visit.
If a pregnancy  is reported, the Investigator should inform GSK within 24 hours of
learning of the pregnancy  and should follow the procedures outlined in 
Section 12.6, Appendix 6 .
Abnormal pregnancy  outcomes (e.g., spontaneous abortion,
fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
9.2.6. Total Blood Volume
No more than 500 mL of blood will be collected over the duration of the study, from an 
individual participant, including an y extra assessments that ma y be required.
9.3. Treatment of Overdose
For this study , any  dose of GSK2838232 greater than the planned dose for any  given 
participant in each treatment period within a 24 -hour time period ( 1 hour) will be 
considered an overdose.
For this study  any dose of RTV greater than the planned dose (100 mg once daily ) within 
a 24-hour time period ( 1 hour) will be considered an overdose.
In the event of an overdose the Investigator or treating phy sician should:
Contact the GSK Medical Monitor immediately .
Closely  monitor the participant for AEs/SAEs and laboratory  abnormalities until 
GSK2838232 can no longer be detected s ystemically  (at least 7 day s for 
GSK2838232).
Obtain a plasma sample for PK anal ysis within 5 day s from the date of the last 
dose of study  treatment if requested b y the Medical Monitor (determined on a 
case-by-case basis).
Document the quantit y of the excess dose as well as the duration of the 
overdosing in the CRF.
Decisions regarding dose interruptions or modifications will be made by  the Investigat or
in consultation with the Medical Monitor based on the clinical evaluation of the 
participant.
2017N322544_01 CONFIDENTIA L
205820
519.4. Safet y Assessments
Planned time points for all safety  assessments are provided in the Schedule of 
Assessments ( Table 2 and Table 3).
9.4.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respiratory , Gastrointestinal and Neurological s ystems.  Height 
and weight will also be measured and recorded.
A brief ph ysical examination will include, at a minimum assessments of the lungs, 
cardiovascular s ystem and abdomen (liver and spleen).
Investigator s should pay  special attention to clinical signs related to previous 
serious illnesses.
9.4.2. Vital Signs
Vital signs will be measured in supine position after 10 minutes rest and will 
include sy stolic and diastolic blood pressure (BP) and heart rate (HR);
BP and HR to be taken in triplicate (taken 5 minutes apart) at pre -dose (Part 1: 
Day 1; Part 2: Day  1 and Day  11) an d singular at all other measurement time 
points;
If a blood pressure is outside the normal limits (< 90mmHg or > 160mmHg), 
then additional measurements should be taken each minute for 2 more 
occasions.
If a HR is outside the normal limits (< 40 bpm or > 100 bpm) then additional 
measurements should be taken 5 minutes apart for 2 more occasions.
Ensure correct sized cuff is used for arm circumference.
It is acceptable that HR be captured from continuous ECG equipment, 12 -lead 
ECG or BP equipment.
The GSK Me dical Monitor should be notified for any  clinically  significant 
changes in vital signs.
9.4.3. Electrocardiograms
Triplicate 12 -lead ECGs will be obtained at least 5 minutes apart in the supine 
position after 10 minutes of rest pre -dose (Part 1: Day  1; Part 2: Da y 1 and 
Day 11).  All values will be recorded.
Singular 12- lead ECGs will be recorded at all other timepoints using an ECG 
machine that automatically  calculates the HR and measures PR, QRS, QT and 
QTcF intervals.
2017N322544_01 CONFIDENTIA L
205820
52Refer to Section 8.1.2 for QTc withdrawal criteria and additional QTc readings 
that may  be necessary .
The Investigator will review the 12 -lead ECGs.  The decision to run repeat 
measurements if a result is outside of the normal predicted range (and/or 
considered clinically  significant) should be made by  the PI based on their 
clinical judgement to ensure participant safet y.
9.4.4. Holter Monitoring
Cardiac monitoring (24 hour) will be performed using Holter monitoring during the 
screening process as shown in the Schedule of Asses sments ( Table 2 and Table 3).  
Holter monitoring may  take place during the study period if needed.
Start date and time, stop date and time, interpretation, and nature of abnormality , if an y, 
will be captu red in the study  database.  Anal ysis of the Holter monitoring will consider 
the following:
HR (brad y and tach ycardia).
Normal and aberrant beats.
Number of supraventricular contractions, premature atrial contractions, 
supraventricular tach ycardias, prematu re ventricular contractions, couplets, 
triplets and ventricular tachy cardias.
Atrio
-ventricular conduction defects.
Atrial fibrillation and flutter.
9.4.5. Clinical Safety  Laboratory  Assessments
Refer to Section 
12.2, Appendix 2for the list of clinical laboratory  tests to be 
performed and to the Schedule of Assessments ( Table 2and Table 3) for the 
timing and frequency .
The Investigator must review the laborato ry report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF.  The laboratory  reports must be filed with the source 
documents.  Clinically  significant abnormal laboratory  findings are t hose which 
are not associated with the underl ying disease, unless judged b y the Investigator
to be more severe than expected for the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within 7 day s afte r the last dose of study  
treatment should be repeated until the values return to normal or baseline or are 
no longer considered significantly  abnormal by  the Investigator or medical 
monitor.
If such values do not return t o normal/baseline within a period of time judged 
reasonable b y the Investigator , the etiology  should be identified and the sponsor 
notified.
2017N322544_01 CONFIDENTIA L
205820
53All protocol -required laboratory  assessments, as defined in Section 12.2, 
Appendix 2, must be conducted in accordance with the laboratory  manual and 
the Schedule of Assessments ( Table 
2and Table 3 ).
If laboratory  values from non- protocol specified laboratory  assessm ents 
performed at the institution’s local laboratory  require a change in participant 
management or are considered clinically  significant by  the Investigator (e.g., 
SAE or AE or dose modification), then the results must be recorded in the CRF.
9.5. Pharmacokine tics
9.5.1. Blood sample collection
Blood samples for PK and metabolism analy sis of GSK2838232 will be 
collected at the time points indicated in Schedule of Assessments ( Table 2 and 
Table 3).  The actual date an d time of each blood sample collection will be 
recorded.  The timing of PK samples may be altered and/or PK samples may  be 
obtained at additional time points to ensure thorough PK monitoring.  This will 
not require an amendment to the protocol.
Details of PK blood sample collection (including volume to be collected), processing, 
storage and shipping procedures are provided in the SRM.
9.5.2. Sample analy sis
Concentrations of GSK2838232 will be determined in plasma using the currentl y 
approved bioanaly tical methodo logy.  Raw data will be archived in the GLP Archives, 
GSK.
Once the plasma has been anal yzed for GSK2838232, any  remaining sample 
may be anal yzed for other compound -related metabolites and the results 
reported under a separate PTS -DMPK, GlaxoSmithKline protocol.
9.6. Pharmacody namics
Not applicable.
9.7. Genetics
Not applicable.
9.8. Biomarkers
Not applicable.
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Not applicable.
2017N322544_01 CONFIDENTIA L
205820
549.10. DATA MANAG EMENT
For this study  participant data will be entered into ClinBase, transmitted 
electronically  to GSK or designee and combined with data provided from other 
sources in a validated data system.
Management of clinical data will be performed in accordance with applicable 
GSK standards and data cleaning procedures to ensure t he integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary for Regulatory  Activities) and an internal validated 
medication dictionary , GSK Drug.
CRFs (including queries and audit trails) will be retained b y PAREXEL, and a 
copy  of the annotated CRF will be sent to GSK.  Participant initials will not be 
collected or transmitted to GSK according to GSK policy .
10. STATISTICA L CONSIDERA TIONS
All stat istical analy ses will be performed b y PAREXEL  International Earl y Phase 
Biostatistics.  All statistical anal yses will be performed using the latest available version 
of SAS (SAS I nstitute Inc., Cary , North Carolina, United States of America [USA]), 
version 9.3 or higher.  PK parameters will be calculated using Phoenix WinNonlin
(Certara, L.P., 1699 S Hanley  Road, St Louis MO 63144 USA), version 6.3 or higher.
Complete details will be documented in the Reporting and Analy sis Plan (RAP).
Any deviations from t he planned anal yses will be described in the clinical study  report.
10.1. Sample Size Determination
Sample sizes are based on prior relative bioavailability studies with GSK2838232 and 
take into account variability  and logistical factors while no formal calculation of power or 
sample size for Parts 1 or 2 of the study  was performed.  A sample size of approximately  
16participants for Part 1 and 10 participants for Part 2, considering a drop -out rate of 
25%, of the stud y should be sufficient to provide useful esti mates of inter -participant 
variability  for GSK2838232 PK parameters and safet y assessments.
Additional participants will be randomized and enrolled to ensure a minimum of 
12evaluable participants for Part 1 (crossover of tablet and capsule) and 8 evaluabl e 
participants for Part 2 (6 active: 2placebo).
Sample size assumptions
For Part 1 of the study : The between -subject variability  (%CVb) for AUC(0 -), and 
Cmax parameters from previous studies at 
different doseswere 21% to 47% and 41% to 
44%, respectively .  Assuming within -subject variability  (%CVw ) for AUC(0 -) and 
Cmax is 80% of highest between- subject variability  (which will be 38% and 35%, 
respectivel y), and with the sample size of 12, it is estimated that the precision (i.e., half 
2017N322544_01 CONFIDENTIA L
205820
55width of the 90% con fidence interval on the log scale) for the relative bioavailability  
assessment will be within 31.7% of the point estimate for AUC(0 -), and within 29.0% 
of the point estimate for Cmax. If the point estimate of the ratio of geometric mean for 
Cmax is 1, th en 90% confidence interval will be approximately  (0.78, 1.29).
10.2. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
All Participants Screened Population
The All Participants Screened Population will include all partici pants who consent to 
participate in the clinical study . Participants in this population will be used for 
disposition summary .
Safety Population
The Safet y Population will include all participants who received at least 1 dose of the 
study  treatment (including placebo) with at least 1 post -baseline safety  assessment.  
Participants in this population will be used for all demographic and safet y summaries or 
listings.  The population will be defined separately for Part 1A, Part 1B and Part 2 of the 
study .
Pharm acokinetic Population
The PK Population will include all participants in the Safet y population for whom at least 
oneevaluable PK sample is obtained and anal yzed.  Pharmacokinetic samples that may  
be affected b y protocol deviations will be reviewed by  the 
study  team to determine 
whether or not the sample will be excluded.  All PK anal yses will be based on this 
analysis population.  The population will be defined separatel y for Part 1A, Part 1B, and 
Part2 of the study .
10.3. Definition of Baseline
Unless specifie d, baseline will be the last value before the first dose of study  treatment. 
10.4. Statistical A nalyses
All safet y anal yses will be performed on the Safety  Population.
All PK analy ses will be performed on the PK Population.
For assessment of relative bioavailab ility of tablet versus capsule (AUC(0 -) and Cmax) 
and effect of food (AUC(0 -), Cmax, and tmax), loge -transformed selected PK
parameters (except tmax) will be anal yzed using a mixed effects model.  The point 
estimates and their associated 90% confidence i nterval ( CI)will be provided for the 
2017N322544_01 CONFIDENTIA L
205820
56ratios, test/reference (for bioavailability ) and fed/fasted (food effect) in PKparameter 
values on the original scale.
For the parameter tmax, the corresponding non- parametric anal ysis will be performed on 
the origina l scale using CIs for the estimation of the treatment difference.
Steady -state GSK2838232 concentrations will be assessed by  estimating the slope of pre -
dose concentrations following repeated dail y administration.  Accumulation of plasma 
GSK2838232 will be assessed as the ratios of Day 11/Day 1 AUC(0- ), Cmax, and C 
values.
10.4.1. Safety  Analyses
Clinical safety  observations will include AEs, vital sign measurements, ECGs and 
clinical laboratory  measurements (hematology , clinical chemistry  and urinaly sis).  Safet y 
data will be tabulated and, where appropriate, analy zed by  the use of descriptive 
statistics.
The number (%) of participants withdrawing from the study  treatment, study  and reason 
for withdrawal will be summarized for each treatment with placebo particip ants 
combined within each study  part.
Reported AEs will be coded using Medical Dictionary  for Regulatory  Activities 
(MedDRA).  The number (%) of participants with treatment- emergent AEs (TEAEs) and 
treatment -related AEs will be tabulated by  system organ cl ass (SOC), preferred term and 
by treatment group within each study  part.  Severity  of the TEAEs and treatment -related 
AEs will also be summarized by  SOC, preferred term and b y treatment group within each 
study  part.  Deaths, SAEs and AEs leading to withdrawal will be listed.
Descriptive statistics for observed and change from baseline in laboratory  parameters (if 
applicable), vital signs measurements and ECGs will be presented b y treatment group 
within each study  part.  Clinical laboratory  toxicities will b e graded based on the Division 
of AIDS (DAIDS) grading s ystem, as specified in Section 12.4, Appendix 4.  Summaries 
of lab
oratory toxicity  grade will be provided.
10.4.2. Pharmacokinetic A nalyses
The following pla sma PK parameters will be determined using standard 
non-compartmental methods as data permit and in compliance with the GlaxoSmithKline 
SOP:
Part 1:
AUC(0 -t)
AUC(0 -)
Cmax
C24
2017N322544_01 CONFIDENTIA L
205820
57tlag
tmax
t½
tlast
Part 2:
Day 1 dose:
AUC(0 -)
Cmax
C
tmax
tlag
Day 11 dose:
AUC(0 -)
AUC(0 -)
Cmax
C
tmax
t½
tlast
Accumulation:
R(AUC(0 -))
R(Cmax)
R(C)
Any additional PK parameters that are calculated will be provided in the RAP.  Actual 
elapsed times from dosing will be used in the PK anal ysis.  The AUC will be determined 
using the linear -up/log -down trapezoidal rule.  Individual PK parameter values will be 
listed, and a descriptive summary  by treatment will be provided.
Pharmacokinetic data will be presented in graphical and/or tabular form and will be 
summarized descriptively .  Plasma GSK2838232 concentration -time data will be listed 
by participant, treatment group and time and summarized by  treatment group and time for 
each part of the study.  Individual participant profiles for GSK2838232 
concentration -time data will be presented on both a linear and semi- log scale.  L inear and 
semi -
log figures for mean and median GSK2838232 plasma concentrations versus time 
will also be generated.
2017N322544_01 CONFIDENTIA L
205820
5810.4.2.1. Relative Bioavailability
In Part 1A, the following plasma PK parameters will be assessed to det ermine the relative 
bioavailability  as data permit:
AUC(0 -)
Cmax
The dependent variable will be the log -
transformed PK parameters of interest (AUC(0- ) 
and Cmax) and the independent variables will include a fixed effect for treatment (table 
or capsule), s equence and period, and participant as a random effect. The estimated 
difference and CI obtained on the log scale will be exponentiated to provide an estimate 
of the table to capsule ratio and its associated 90% CI .
10.4.2.2. Food Effect
Food effect will be assesse d in Part 1 using Analysis of Variance (ANOVA).  The 
dependent variable will be the log- transformed PK parameters of interest (AUC(0 -∞) and 
Cmax) and the independent variables will include a fixed effect for treatment (with or 
without food) and subject as a random effect.  The estimated difference and confidence 
interval (CI) obtained on the log scale will be exponentiated to provide an estimate of the 
fed to fasted ratio and its associated 90% CI.
10.4.2.3. Steady  State A ssessments
For Part 2, mean plasma GSK2838232 pre-dose values between Day s 2 through 11 and 
Cof Day  11 will be plotted against time.  Achievement of plasma GSK2838232 steady -
state will be assessed b y calculating the 90% CI of the slope of the linear regression of 
log(C) versus time.  The dependen t variable in the linear regression model will be 
log(C) and the model will include a random intercept effect for participant and a fixed 
slope effect for stud y day.  Steady state will be reached if the 90% CI for the slope 
estimate includes zero.
10.4.2.4. Accumu lation
For Part 2, the extent of accumulation of GSK2838232 will be evaluated by comparing 
AUC(0 -), Cmax and Cτ between Day  11 and Day 1.  For each of these comparisons an 
analysis of variance will be conducted on the log scale.  The difference between Day 11 
and Day  1 least square (LS) means and a 90% CI will be computed by  fitting a mixed 
effects model with the log- transformed PK parameter as the dependent variable, day  as a 
fixed effect and participant as a random effect.  The estimated difference and confidence 
interval obtained on the log -scale will be exponentiated to provide an estimate of the 
Day11 to Day  1 ratio and its associated 90% CI.  If the model fails to converge, 
participants will be fit as a fixed effect.
10.4.3. Efficacy  Analyses
Not applicable.
2017N322544_01 CONFIDENTIA L
205820
5910.4.4. Other A nalyses
Not applicable.
10.4.5. Interim A nalyses
The dose and formulation to be administered in Part 1B and Part 2 will be decided, based 
on the outcome and results of an informal analy sis of data from Part 1A of the study .
The Reporting and Anal ysis Plan will describe the planned interim anal yses in greater 
detail.
2017N322544_01 CONFIDENTIA L
205820
6011. REFERENCES
GlaxoSmithKline Document Number 2012N151889_03 Compound GSK2838232. 
Investigator's Brochure, Version 03. 11 Nov 2016.
James L .P. Pharmacokinetics of Acetaminophen -Protein Adducts L iver Failure. Drug 
Metab Disp, 37:1779- 1784. 2009
NORVIR (ritonavir) Product I nformation. January , 2013.
Qian K, Morris -Natschke SL  and Lee KH. HIV entry  inhibitors and their potential in HI V 
therap y. Medicinal Research Reviews, 2009;29:369 -93.
U.S. Department of Agriculture and U.S. Department of Health and Human Services. 
Dietary Guidelines for Americ ans, 2010. 7th Edition, Washington, DC: U.S. Government 
Printing Office, December 2010.
United Nations program on HIV/AIDS (UNAIDS), Fact Sheet 2015. Available from 
www.UNAIDS.org
2017N322544_01 CONFIDENTIA L
205820
6112. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
AE Adverse Event
AIDS Acquired Immunodeficiency Syndrome
ALT Alanine Aminotransferase
ANOVA Analysis of Variance
API Active Pharmaceutical Ingredient
ARV Antiretroviral
AST Aspartate Aminotransferase
AUC (0 -t) Area under the concentration -time curve from zero up to a definite 
time t
AUC(0 -) Area under the curve (Area under the plasma drug concentration -
time curve from pre -dose to the end of the dosing interval at 
steady state)
AUC(0 -inf) Area under the concentration -time curve from time zero (pre -dose) 
extrapolated to infinite time
AV Atrioventricular
BID Twice Daily
BMI Body Mass Index
BP Blood Pressure
CFR Code of Federal Regulations
CI Confidence Interval
Cmax Maximum observed concentration
Con Med Concomitant medication
CONSORT Consolidated Stan dards of Reporting Trials
CRF Case Report Form
CRO Contract Research Organization
CV Cardiovascular
CYP Cytochrome P subfamily of enzymes
DAIDS Division of AIDS
DDI Drug -drug Interaction
ECG Electrocardiogram
ERCP Endoscopic retrograde cholangio -pancreatography
FDA Food and Drug Administration
FSH Follicle Stimulating
FTiH First Time in Human
GCSP Global Clinical Safety and Pharmacovigilance
GSK GlaxoSmithKline
HbsAg Hepatitis B surface Antigen
hCG Human Chorionic Gonadotrophin
HCV Hepatitis C Virus
Hem/Chem Hematology and Clinical Chemistry
HIV Human Immunodeficiency Virus
2017N322544_01 CONFIDENTIA L
205820
62HR Heart Rate
HRT Hormone Replacement Therapy
IB Investigator’s Brochure
IEC Independent Ethics Committees
IRB Institutional Review Board
MedDRA Medical Dictionary for Regulatory Activities
MSDS Material Safety Data Sheet
NOAEL No Adverse Event Dose Level
PI Principal Investigator
PiB Powder in Bottle
PK Pharmacokinetic(s)
QD Once daily
RAP Reporting and Analysis Plan
RTV Ritonavir
SAE Serious Adverse Event
SOC System Organ Class
SOP Standard Operating Procedure
SRM Study Reference Manual
SSD Spray Dried Dispersion
SUSAR Suspected Unexpected Serious Adverse Reactions
t1/2 Apparent terminal phase half -life
TEAE Treatment -Emergent Adverse Event
tlag Lag-time (time delay between drug administration and first 
observed
tmax Time of occurrence of Cmax
ULN Upper Limit of Norma
US United States (of America)
WOCBP Women of child bearing potential
WPW Wolf Parkinson White syndrome
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
NONE Norvir
Phoenix
SAS
WinNonlin
2017N322544_01 CONFIDENTIA L
205820
6312.2. Appendix 2: Clinical Laboratory  Tests
Hematology , clinical chemistry , urinal ysis and additiona l parameters to be tested are 
listed below:
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC 
Indices :WBC count with 
Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical Chemistry 1 BUN Potassium Aspartate 
Aminotransferase 
(AST) / Serum 
Glutamic-
Oxaloacetic 
Transaminase 
(SGOT)Total and direct 
bilirubin
Creatinine Sodium Alanine 
Aminotransferase 
(ALT) / Serum 
Glutamic- Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose Calcium Alkaline 
phosphataseAlbumin
Triglycerides Cholesterol (total cholesterol, HDL, LDL, VLDLc 
(calculated) and Non -HDLc [calculated])
Lipase
Routine Urinalysis Specific gravity
pH, glucose, protein, blood and ketones by dipstick
Microscopi c examination (if blood or protein is abnormal)
Other Screening Tests HIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody)
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opiates, cannabinoids and benzodiazepines)
FSH and estradiol (as appropriate)
Serum hCG Pregnancy test (as appropriate)2
NOTES:
1Details of Liver Chemistry Stopping Criteria and Required Actions and Follow- Up Assessments 
after liver stopping or monitoring event are given in Section 8.1.1 and Section 12.2, Appendix 2.
2Serum testing will be performed at Screening testing.
2017N322544_01 CONFIDENTIA L
205820
6412.3. Appendix 3 : Liver Safety : Required A ctions and Follow -up 
Assessments
Phase 1 L iver chemistry  stopping criteria have been designed to assure participant safet y 
and to evaluate liver event etiology  (in alignment with the FDA premarketing clinical 
liver safet y guidance).
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM 174090.pdf.
Phase I liver chemistry stopping criteria and required follow up assessments
Liver Chemistry Stopping Criteria 
ALT -absoluteALT ≥3 x ULN
If ALT ≥ 3 x UL N AND bilirubin1,22 x UL N (> 35% direct 
bilirubin) or  INR > 1.5, Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Report the event to GSK within 
24hours
Complete the liver event CRF, and 
complete an SAE data collection tool if 
the event also meets the criteria for an 
SAE2
Perform liver event follow up 
assessments 
Monitor the participant until liver 
chemistries resolv e, stabilise, or return 
to within baseline (see MONITORING
below)
MONITORING:
If ALT ≥ 3 x ULN AND bilirubin 
2 xULN or INR > 1.5
Repeat liver chemistries (include ALT, 
AST, alkaline phosphatase, bilirubin) 
and perform liver event follow up Viral hepatitis serology3
Obtain INR and recheck with each 
liver chemistry  assessment until the 
transaminases val ues show downward 
trend
Obtain blood sample for 
pharmacokinetic (PK) analy sis.
Serum creatine phosphokinase (CPK) 
and lactate deh ydrogenase (LDH).
Fractionate bilirubin, if total bilirubin 
2 x UL N
Obtain complete blood count with 
differential to assess e osinophilia
Record the appearance or worsening of 
clinical sy mptoms of liver injury , or 
hypersensitivity , on the AE report 
form
2017N322544_01 CONFIDENTIA L
205820
65Liver Chemistry Stopping Criteria 
assessments within 24 hours
Monitor participants twice weekl y until 
liver chemistries resol ve, stabilise or 
return to within baseline
A specialist or hepatology consultation 
is recommended
If ALT ≥ 3 x ULN AND bilirubin 
< 2 x ULN and INR ≤ 1.5:
Repeat liver chemistries (include ALT, 
AST, alkaline phosphatase, bilirubin) 
and perform liver event f ollow up 
assessments within 24 to 72 hours
Monitor participants weekly  until liver 
chemistries resolve, stabilize or return to 
within baselineRecord use of concomitant 
medications on the concomitant 
medications report form including 
acetaminophen, herbal remedies, other
over the counter medications.
Record alcohol use on the liver event 
alcohol intake case report form
If ALT ≥ 3 x ULN AND bilirubin 
2 xULN or INR > 1.5:
Anti- nuclear antibody , anti -smooth 
muscle antibody , Type 1 anti- liver 
kidney  microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG) or gamma globulins.
Serum acetaminophen adduct high 
performance liquid chromatograph y 
(HPL C) assay  (quantifies potential 
acetaminophen contribution to liver 
injury  in participants with definite or 
likely  acetaminophen use in the 
preceding week [ James, 2009].
Liver imaging (ultrasound, mag netic 
resonance, or computerised 
tomograph y) and /or liver biopsy  to 
evaluate liver disease; complete L iver 
Imaging and/or Liver Biopsy  CRF 
forms.
1.Serum bilirubin fractionation should be performed if testing is available.  If serum 
bilirubin fractionation is not immediately  available, discontinue study  treatment for 
that participant if ALT 3 x ULN and bilirubin  2 x ULN.  Additionally , if serum 
bilirubin fractionation testing is unavailable, record presence of detectable urinary  
bilirubin on dipstick, i ndicating direct bilirubin elevatio ns and suggesting liver injury .
2.All events of ALT 3 x ULN and bilirubin  2 x ULN (> 35% direct bilirubin) or 
ALT 3 x ULN and INR > 1.5, if INR measured, which may  indicate severe liver 
injury  (possible ‘Hy ’s Law’), m ust be reported as an SAE (excluding studies of 
hepatic impairment or cirrhosis); INR measurement is not required and the threshold 
value stated will not apply to participants receiving anticoagulants .
2017N322544_01 CONFIDENTIA L
205820
663.Includes: Hepatitis A IgM antibody ; Hepatitis B surfac e antigen and Hepatitis B Core 
Antibody  (IgM); Hepatitis C RNA; Cy tomegalovirus IgM antibody ; Epstein -Barr 
viral capsid antigen IgM antibody  (or if unavailable, obtain heterophile antibody  or 
monospot testing); Hepatitis E IgM antibod y.
2017N322544_01 CONFIDENTIA L
205820
6712.4. Appendix 4: Divisio n of A IDS Table For Grading The 
Severit y of Adult and Pediatric A dverse Events
The DAIDS Table [ Division if AIDS (DAIDS) Table (NIH), 2014] will be used to grade 
the severit y of an AE that is not specifically identified in the grading table.  I n addition, 
all deaths related to an AE are to be classified as grade 5.
ParameterGrade 1
MildGrade 2 
ModerateGrade 3 
SevereGrade 4 
Potentially Life 
Threatening
Clinical 
adverse event 
NOT
identified 
elsewhere in 
the grading 
tableMild sy mptoms 
causing no or 
minimal 
interference 
with usual 
social & 
functional 
activities with 
intervention not 
indicatedModerate 
symptoms 
causing greater 
than minimal 
interference with 
usual social & 
functional 
activities with 
intervention 
indicatedSevere s ymptoms 
causing inability to 
perform usual 
social & functional 
activities with 
intervention or 
hospitalization 
indicatedPotentially  life-
threatening 
symptoms causing 
inability  to perform 
basic self -care 
functions with 
intervention 
indicated to prevent 
permanent 
impairment, 
persis tent disability , 
or death
2017N322544_01 CONFIDENTIA L
205820
68Major Clinical Conditions Grading Table
Cardiovascular:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Arrhythmia
(by ECG or phy sical
examination)
Specify type, if 
applicableNo sy mptoms AND
No intervention 
indicatedNo sy mptoms AND Non-
urgent intervention 
indicatedNon-life-threatening 
symptoms AND Non-
urgent
intervention indicatedLife-threatening arrhy thmia OR
Urgent intervention indicated
Blood Pressure
Abnormalities 1
Hypertension (with the 
lowest reading taken 
after repeat testing 
during a visit)
≥ 18 years of age140 to < 160 mmHg 
systolic
OR
90 to < 100 mmHg 160 to < 180 mmHg 
systolic OR
100 to < 110
mmHg diast olic180 mmHg s ystolic
OR
≥110 mmHg diastolicLife-threatening consequences in a 
participant not previously  diagnosed 
with hy pertension (e.g., malignant 
hypertension) OR Hospitalization 
<18 years of age >120/80 mmHg 95th to < 99th pe rcentile 
+5mmHg adjusted for 
age, height, and gender 
(systolic and/or diastolic)9th percentile
+5mmHg adjusted for 
age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences in a 
participant not previously  diagnosed 
with hy perte nsion (e.g., malignant 
hypertension) OR Hospitalization 
indicated
Hypotension No sy mptoms Symptoms corrected with 
oral fluid replacementSymptoms AND IV
fluids indicatedShock requiring use of vasopressors 
or mechanical assistance to maintain 
blood pressure
2017N322544_01 CONFIDENTIA L
205820
69PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Cardiac Ischemia or
Infarction
Report only oneNot applicable Not applicable New s ymptoms with 
ischemia (stable angina) 
ORNew testing consistent 
with ischemiaUnstable angina OR Acute 
myocardial infarction
Heart Failure No sy mptoms AND
Laboratory  or
cardiac imaging 
abnormalitiesSymptoms with mild to 
moderate activity  or 
exertionSymptoms at rest or with 
minimal activity  or 
exertion (e.g., h ypoxemia) 
ORIntervention indicated 
(e.g., ox ygen)Life-threatening consequences OR
Urgent intervention indicated (e.g., 
vasoactive medications, ventricular 
assist device, heart transplant)
Haemorrhage
(with significant acute
blood loss)Not applicable Symptoms AND No 
transfusion indicatedSymptoms AND
Transfusion of  2 units 
packed RBCs indicatedLife-threateni ng hy potension OR
Transfusion of > 2 units packed 
RBCs (for children, packed RBCs
>10 cc/kg) indicated
Prolonged PR Interval 
or AV Block
Report only one
>16 years of agePR interval 0.21 to 
<0.25 secondsPR interval ≥ 0.25
seconds ORType I
2nd degree AV blockType II 2nd degree AV 
block OR Ventricular 
pause 3.0 secondsComplete AV block
≤ 16 years of age 1st degree AV block
(PR interval 
>normal for age and 
rate)Type I 2nd degree AV
blockType II 2nd d egree AV 
block OR Ventricular 
pause ≥ 3.0 secondsComplete AV block
Prolonged QTc
Interval 20.45 to 0.47 seconds >0.47 to 0.50 seconds >0.50 seconds OR
06 seconds above 
baselineLife-threatening consequences (e.g., 
Torsade de pointes, other associated 
serious ventricular d ysrhythmia)
2017N322544_01 CONFIDENTIA L
205820
70PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Thrombosis or
Embolism
Report only oneNot applicable Symptoms AND No 
intervention indicatedSymptoms AND
Intervention indicatedLife-threatening embolic event (e.g., 
pulmonar y embolism, thrombus)
1.Blood pressure norms for children < 18 years of age can be found in: Expert Panel on Integrated Guidelines for Cardiovascular Health 
and Risk Reduction in Children and Adolescents.  Pediatrics 2011;128;S213; originally published onli ne November 14, 2011; DOI : 
10.1542/peds.2009-2107C
2.As per Bazett’s formula
2017N322544_01 CONFIDENTIA L
205820
71Dermatologic:
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Alopecia (scalp onl y) Detectable b y study 
participant, caregiver, or 
physician AND Causing no 
or minimal interference 
with usual social & 
functional activitiesObvious on visual 
inspection AND
Causing greater than 
minimal interference 
with usual social & 
functional activitiesNot applicable Not applicable
Bruising Localized to one area Localized to more than 
one areaGeneralized Not applicable
Cellulitis Not applicable Non-parenteral 
treatment indicated 
(e.g., oral antibiotics, 
antifungals, antivirals)IV treatment indicated (e.g., 
IV antibiotics, antifungals, 
antivirals)Life-threatening 
consequences (e.g., sepsis, 
tissue necrosis)
Hyperpigmentation Slight or localized causing 
no or minimal interference 
with usual social & 
functional activitiesMarked or generalized 
causing greater than 
minimal interference 
with usual soci al & 
functional activitiesNot applicable Not applicable
Hypopigmentation Slight or localized causing 
no or minimal interference 
with usual social & 
functional activitiesMarked or generalized 
causing greater than 
minimal interference 
with usual social & 
functional activitiesNot applicable Not applicable
Petechiae Localized to one area Localized to more than 
one areaGeneralized Not applicable
2017N322544_01 CONFIDENTIA L
205820
72PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Pruritus1
(without skin lesions)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater 
than minimal 
interference with usual 
social & functional 
activitiesItching causing inability  to 
perform usual social & 
functional activitiesNot applicable
Rash
Specify type, if applicableLocalized rash Diffuse rash OR Target 
lesionsDiffuse rash AND Vesicles 
or limited number of bullae 
or superficial ulcerations of 
mucous membrane limited 
to one siteExtensive or generalized 
bullous lesions OR
Ulceration of mucous 
membrane involving two or 
more distinct mucosal sites 
ORStevens -Johnson 
syndrome ORToxic 
epidermal necrol ysis1.For pruritus associated with injections or infusions, see the Site Reactions to Injections and Infusions section
2017N322544_01 CONFIDENTIA L
205820
73Endocrine and Metabolic:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Diabetes Mellitus Controlled without 
medicationControlled with 
medication OR
Modification of current 
medication regimenUncontrolled despite 
treatment modification 
ORHospitalization for 
immediate glucose control 
indicatedLife-threatening 
consequences (e.g., 
ketoacidosis, hy perosmolar 
non- ketotic coma, end organ 
failure)
Gynaecomastia Detectable b y study 
participant, caregiver, or 
physician AND Causing 
no or minimal 
interference with usual 
social & functional 
activitiesObvious on visual 
inspection AND Causing 
pain with greater than 
minimal interference with 
usual social & functional 
activitiesDisfiguring changes AND
Symptoms requiring 
intervention or causing 
inability  to perform usual 
social & functional 
activitiesNot a pplicable
Hyperthyroidism No sy mptoms AND
Abnormal laboratory  
valueSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities ORThyroid 
suppression therap y 
indicatedSymptoms causing 
inability  to perform usual 
social & functional 
activities OR
Uncontrolled despite 
treatment modificationLife-threatening 
consequences (e.g., thy roid 
storm)
2017N322544_01 CONFIDENTIA L
205820
74PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Hypothyroidism No sy mptoms AND
Abnormal laboratory  
valueSymptoms causing 
greater than minimal 
interference with usual 
social & functi onal 
activities OR Thy roid 
replacement therap y 
indicatedSymptoms causing 
inability  to perform usual 
social & functional 
activities OR
Uncontrolled despite 
treatment modificationLife-threatening 
consequences (e.g., 
myxedema coma)
Lipoatrophy 1 Detectable b y study 
participant, caregiver, or 
physician AND Causing 
no or minimal 
interference with usual 
social & functional 
activitiesObvious on visual 
inspection AND Causing 
greater than minimal 
interference with usu al 
social & functional 
activitiesDisfiguring changes Not applicable
Lipohypertrophy 2 Detectable b y study 
participant, caregiver, or 
physician AND Causing 
no or minimal 
interference with usual 
social & functio nal 
activitiesObvious on visual 
inspection AND Causing 
greater than minimal 
interference with usual 
social & functional 
activitiesDisfiguring changes Not applicable
1.Definition: A disorder characterized b y fat loss in the face, extremities, and buttocks.
2.Definition: A disorder characterized b y abnormal fat accumulation on the back of the neck, breasts, and abdomen.
2017N322544_01 CONFIDENTIA L
205820
75Gastrointestinal:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Anorexia Loss of appetite wit hout 
decreased oral intakeLoss of appetite 
associated with 
decreased oral intake 
without significant 
weight lossLoss of appetite 
associated with 
significant weight lossLife-threatening 
consequences OR
Aggressive intervention 
indicated (e.g., tube feedin g, 
total parenteral nutrition)
Ascites No sy mptoms Symptoms AND
Intervention indicated 
(e.g., diuretics, 
therapeutic paracentesis)Symptoms recur or 
persist despite 
interventionLife-threatening 
consequences
Bloating or Distension
Report only oneSymptom s causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activitiesSymptoms causing 
inability  to perform usual 
social & functional 
activitiesNot appli cable
Cholecystitis Not applicable Symptoms AND Medical 
intervention indicatedRadiologic, endoscopic, 
or operative intervention 
indicatedLife-threatening 
consequences (e.g., sepsis, 
perforation)
Constipation Not applicable Persistent constipation 
requi ring regular use of 
dietary  modifications, 
laxatives, or enemasObstipation with manual 
evacuation indicatedLife-threatening 
consequences (e.g., 
obstruction)
2017N322544_01 CONFIDENTIA L
205820
76PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Diarrhoea
≥ 1 year of ageTransient or intermittent 
episodes of unformed 
stools OR Increase of 3 
stools over baseline per 
24-hour periodPersistent episodes of 
unformed to watery  
stools 
ORIncrease of 
4 to 6 stools over 
baseline per 24 -hour 
periodIncrease of 7 stools per 
24-hour period ORIV 
fluid replacement 
indicatedLife-threatening 
consequences (e.g., 
hypotensive shock)
<1 year of age Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with 
increased number of 
stools OR Mild 
dehydrationLiquid stools with 
moderate deh ydrationLife-threatening 
consequences (e.g., liquid 
stools resulting in severe 
dehy dration, hy potensive 
shock)
Dysphagia or Odynophagia
Report only one and specify 
locationSymptoms but able to eat 
usual dietSymptoms causing 
altered dietary  intake 
with no intervention 
indicatedSymptoms causing 
severel y altered dietary  
intake with intervention 
indicatedLife-threatening reduction in 
oral intake
Gastrointestinal
BleedingNot requiring intervention 
other than iron supplementEndoscopic intervention 
indicatedTransfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock)
Mucositis or Stomatitis
Report only one and specify 
locationMucosal ery thema Patchy  
pseudomembranes or 
ulcerationsConfluent 
pseudomembranes or 
ulcerations OR Mucosal 
bleeding with minor 
traumaLife-threatening 
consequences (e.g., 
aspiration, choking) OR 
Tissue necrosis OR Diffuse 
spontaneous mucosal 
bleeding
2017N322544_01 CONFIDENTIA L
205820
77PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Nausea Transient (< 24hours) or 
intermittent AND No or 
minimal interferenc e with 
oral intakePersistent nausea 
resulting in decreased 
oral intake for 24 to 
48hoursPersistent nausea 
resulting in minimal oral 
intake for > 48hours OR 
Rehy dration indicated 
(e.g., IV fluids)Life-threatening 
consequences (e.g., 
hypotensive shock)
Pancreatitis Not applicable Symptoms with 
hospitalization not 
indicatedSymptoms with 
hospitalization indicatedLife-threatening 
consequences (e.g., 
circulatory  failure, 
haemorrhage, sepsis)
Perforation (colon or 
rectum)Not applicable Not applicable Intervention indicated Life-threatening 
consequences
Proctitis Rectal discomfort with no 
intervention indicatedSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Medical 
intervention indicatedSymptoms causing 
inability  to perform usual 
social & functional 
activities OR Operative 
intervention indicatedLife-threatening 
consequences (e.g., 
perforation)
Rectal Discharge Visible discharge Discharge requiring the 
use of padsNot applicable Not applicable
Vomiting Transient or intermittent 
AND No or minimal 
interference with oral 
intakeFrequent episodes with 
no or mild dehy drationPersistent vomiting 
resulting in orthostatic 
hypotension OR 
Aggressive reh ydration 
indicated (e.g., IV fluids)Life-threatening 
consequenc es (e.g., 
hypotensive shock)
2017N322544_01 CONFIDENTIA L
205820
78Musculoskeletal:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Arthralgia Joint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causi ng 
greater than minimal 
interference with usual 
social & functional 
activitiesJoint pain causing inability  
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability  to perform basic 
self-care functions
Arthritis Stiffness or joint swelling 
causing no or minimal 
interference with usual 
social & functional 
activitiesStiffness or joint 
swelling causing greater 
than minimal 
interference with usual 
social & functional Stiffness or joint swelling 
causing inability  to per form 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability  to 
perform basic self -care 
functions
Myalgia (generalized) Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pa in causing 
greater than minimal 
interference with usual 
social & functional 
activitiesMuscle pain causing 
inability  to perform usual 
social & functional 
activitiesDisabling muscle pain 
causing inability  to perform 
basic self -care functions
Osteonecrosis Not applicable No sy mptoms but with 
radiographic findings 
AND No operative 
intervention indicatedBone pain with 
radiographic findings OR
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings 
causing inability  to perform 
basic se lf-care functions
Osteopenia 1
≥ 30 years of age BMD t -score
-2.5 to -1Not applicable Not applicable Not applicable
<30 years of age BMD z -score
-2 to -1Not applicable Not applicable Not applicable
2017N322544_01 CONFIDENTIA L
205820
79PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Oste oporosis 1
≥ 30 years of age Not applicable BMD t -score <-2.5 Pathologic fracture (e.g., 
compression fracture 
causing loss of vertebral Pathologic fracture causing 
life-threatening 
consequences
<30 years of age Not applicable BMD z -score <-2 Pathologic fracture (e.g., 
compression fracture 
causing loss of vertebral 
height)Pathologic fracture causing 
life-threatening 
consequences
1.Bone mineral density (BMD ) t and z scores can be found in: Kanis JA on behalf of the World Health Organization Scientific Group 
(2007).  Assessment of osteoporosis at the primary health- care level.  Technical Report.  World Health Organization Collaborating 
Center for Metabolic Bone Diseases, Universit y of Sheffield, UK. 2007 : Printed by  the University  of Sheffield.
2017N322544_01 CONFIDENTIA L
205820
80Neurologic:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acute CNS Ischemia Not applicable Not applicable Transient ischemic attack Cerebral vascular accident 
(e.g., stroke with 
neurological deficit)
Altered Mental Status (for 
Dementia, see Cognitive, 
Behavioral, or Attentional 
Disturbance below)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy  or 
somnolence causing
greater than minimal 
interference with usual 
social & functional 
activitiesConfusion, memory  
impairment, lethargy , or 
somnolence causing 
inability  to perform usual 
social & functional 
activitiesDelirium ORObtundation 
ORComa
Ataxia Symptoms causing no or 
minimal interference with 
usual social & functional 
activities ORNo sy mptoms 
with ataxia detected on 
examinationSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activitiesSymptoms causing 
inability  to perform usual 
social & functional 
activitiesDisabling s ymptoms 
causing inability  to perform 
basic self -care functions
Cognitive, Behavioural, or 
Attentional Disturbance 
(includes dementia and 
attention deficit disorder)
Specify type, if applicableDisability  causing no or 
minimal interference with 
usual social & functional 
activities ORSpecialized 
resources not indicatedDisability  causing 
greater than minimal 
interference with usual 
social & functional 
activities ORSpecialized 
resources on part -time 
basis indicatedDisability  causing 
inability  to perform usual 
social & functional 
activities ORSpecialized 
resources on a full -time 
basis indicatedDisability  causing inability  
to perform
basic self -care functions OR
Institutionalization 
indicated
2017N322544_01 CONFIDENTIA L
205820
81PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Developmental Delay
<18 years of age
Specify type, if applicableMild developmental delay , 
either motor or cognitive, 
as determined b y 
comparison with a 
developmental screening 
tool appropriate for the 
settingModerate developmental 
delay , either motor or 
cognitive, as deter mined 
by comparison with a 
developmental screening 
tool appropriate for the 
settingSevere developmental 
delay , either motor or 
cognitive, as determined 
by comparison with a 
developmental screening 
tool appropriate for the 
settingDevelopmental regression,
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate 
for the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activitiesSymptoms causing 
inability  to perform usual 
social & functional 
activitiesSymptoms causing inability  
to perform basic self -care 
functions OR
Hospitalization indicated 
ORHeadache with 
significant impair ment of 
alertness or other neurologic 
function
Neuromuscular Weakness 
(includes myopathy and 
neuropathy)
Specify type, if applicableMinimal muscle weakness 
causing no or minimal 
interference with usual 
social & functional 
activities OR No sy mptoms 
with d ecreased strength on 
examinationMuscle weakness 
causing greater than 
minimal interference 
with usual social & 
functional activitiesMuscle weakness causing 
inability  to perform usual 
social & functional 
activitiesDisabling muscle weakness 
causing inability  to perform
basic self -care functions OR 
Respiratory  muscle 
weakness impairing 
ventilation
2017N322544_01 CONFIDENTIA L
205820
82PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Neurosensory Alteration 
(includes paresthesia and 
painful neuropathy)
Specify type, if applicableMinimal paresthesia 
causing no or minimal 
interference with usua l 
social & functional 
activities OR No sy mptoms 
with sensory  alteration on 
examinationSensory  alteration or 
paresthesia causing 
greater than minimal 
interference with usual 
social & functional 
activitiesSensory  alteration or 
paresthesia causing 
inability to perform usual 
social & functional 
activitiesDisabling sensory  alteration 
or paresthesia causing 
inability  to perform basic 
self-care functions
Seizures
New Onset Seizure
≥ 18 y ears of ageNot applicable Not applicable 1 to 3 seizures Prolonged and repetitive 
seizures (e.g., status 
epilepticus) OR Difficult to 
control (e.g.,
refractory  epilepsy )
<18 years of age
(includes new or pre -existing 
febrile seizures)Seizure lasti ng < 5 minutes 
with < 24 hours postictal 
stateSeizure lasting 5 to < 20 
minutes with 
< 24 hours postictal stateSeizure lasting 20 
minutes OR > 24hours 
postictal stateProlonged and repetitive 
seizures (e.g., status 
epilepticus) OR Difficult to 
control (e.g., refractory  
epilepsy )
2017N322544_01 CONFIDENTIA L
205820
83PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Pre-existing Seizure Not applicable Increased frequency  
from previous level of 
control without change in 
seizure characterChange in seizure 
character either in 
duration or quality  (e.g., 
severit y or focality)Prolonged and r epetitive 
seizures (e.g., status 
epilepticus) OR Difficult to 
control (e.g., refractory  
epilepsy )
Syncope Near s yncope without loss 
of consciousness (e.g., pre-
syncope)Loss of consciousness 
with no intervention 
indicatedLoss of consciousness 
AND Hospita lization or 
intervention requiredNot applicable
2017N322544_01 CONFIDENTIA L
205820
84Pregnancy, Puerperium and Perinatal:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Foetal Death or Stillbirth 
(report using mother’s 
participant ID)Not applicable Not applicable Foetal loss occurring at 
20weeks gestationNot applicable
Preterm Delivery 1(report 
using mother’s participant 
ID)Delivery  at 34 to 
< 37 weeks gestational ageDelivery  at 28 to 
<
34 weeks gestational 
ageDelivery  at 24 to 
< 28 weeks gestational 
ageDelivery  at < 24weeks 
gestational age
Spontaneous Abortion or 
Miscarriag2(report using 
mother’s participant ID)
Report only oneChemical pregnancy Uncomplicated 
spontaneous abortion or 
miscarriageComplicated spontaneous 
abortion or miscarriageNot applicable
1.Definition: A delivery  of a live -born neonate occurring at ≥20 to < 37weeks gestational age.
2.Definition: A clinically  recognized pregnancy  occurring at < 20weeks ge stational age.
2017N322544_01 CONFIDENTIA L
205820
85Psychiatric: 
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Insomnia Mild difficulty  falling 
asleep, stay ing asleep, or 
waking up earl yModerate difficulty  
falling asleep, stay ing 
asleep, or w aking up 
earlySevere difficulty  falling 
asleep, stay ing asleep, or 
waking up earl yNot applicable
Psychiatric Disorders 
(includes anxiety , depression, 
mania, and ps ychosis)
Specify disorderSymptoms with 
intervention not 
indicated ORBehavior 
causing no or minimal 
interference with usual 
social & functional 
activitiesSymptoms with 
intervention indicated OR
Behavior causing greater 
than minimal interference 
with usual social & 
functional activitiesSymptoms with 
hospitalization indicated 
ORBehavior causi ng 
inability  to perform usual 
social & functional 
activitiesThreatens harm to self or 
others OR Acute ps ychosis 
ORBehavior causing 
inability  to perform basic 
self-care functions
Suicidal Ideation or
Attempt
Report only onePreoccupied with 
thoughts of death AND
No wish to kill oneselfPreoccupied with 
thoughts of death AND
Wish to kill oneself with 
no specific plan or intentThoughts of killing 
oneself with partial or 
complete plans but no 
attempt to do so OR
Hospitalization indicatedSuicide attempted
2017N322544_01 CONFIDENTIA L
205820
86Respiratory:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acute Bronchospasm Forced expiratory  
volume in 1 second or 
peak flow reduced to 
70 to < 80% ORMild 
symptoms with 
intervention not 
indicatedForced expiratory  volume 
in 1 second or peak flow 
50 to < 70% OR
Symptoms with 
intervention indicated OR
Symptoms causing greater 
than minimal interference 
with usual social & 
functional activitiesForced expiratory  volume 
in 1 second or peak flow 
25 to < 50% OR
Symptoms causing 
inability  to perform usual 
social & functional 
activitiesForced expiratory  volume in 
1 second or peak flow < 25% 
ORLife-threatening 
respiratory  or hemody namic 
compromise OR Intubation
Dyspnoea or Respiratory
Distress
Report only oneDyspnoea on exertion 
with no or minimal 
interference with usual 
social & functional 
activities ORWheezing 
ORMinimal increase in 
respiratory  rate for ageDyspnoea on exertion 
causing greater than 
minimal interference with 
usual social & functional 
activitie s ORNasal flaring 
ORIntercostal retractions 
ORPulse oximetry  90 to 
< 95%Dyspnoea at rest causing 
inability  to perform usual 
social & functional 
activities ORPulse 
oximetry  <90%Respiratory  failure with 
ventilator support indicated 
(e.g., CPAP, BPAP, 
intubation)
2017N322544_01 CONFIDENTIA L
205820
87Sensory:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Hearing Loss
≥12 years of ageNot applicable Hearing aid or 
intervention not 
indicatedHearing aid or 
intervention indicatedProfound bilat eral hearing 
loss (> 80 dB at 2 kHz and 
above) ORNon-serviceable 
hearing (i.e., > 50 dB 
audiogram and < 50% 
speech discrimination)
<12 years of age (based on 
a 1, 2, 3, 4, 6 and 8 kHz 
audiogram)>20 dB hearing loss at 
4kHz>20 dB hearing loss at 
> 4kHz>20 dB hearing loss at 
≥3 kHz in one ear with 
additional speech 
language related services 
indicated (where 
available) OR Hearing 
loss sufficient to indicate 
therapeutic intervention, 
including hearing aidsAudiologic indication for 
cochlear implant and 
additional speech - language 
related services indicated 
(where available)
Tinnitus Symptoms causing no or 
minimal interference with 
usual social & functional 
activities with intervention 
not indicatedSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities with 
intervention indicatedSymptoms causing 
inability  to perform usual 
social & functional 
activitiesNot applicable
2017N322544_01 CONFIDENTIA L
205820
88PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Uveitis No sy mptoms AND
Detectable on examinationAnterior uveitis with 
symptoms OR
Medicam ylasal 
intervention indicatedPosterior or pan- uveitis 
OROperative 
intervention indicatedDisabling visual loss in 
affected ey e(s)
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater 
than minimal 
interference with usual 
social & functional 
activitiesVertigo causing inability  
to perform usual social & 
functional activitiesDisabling vertigo causing 
inability  to perform basic 
self-care functions
Visual Changes
(assessed from baseline)Visual changes causing no 
or minimal interference 
with usual social & 
functional activitiesVisual changes causing 
greater than minimal 
interference with usual 
social & functional 
activitiesVisual changes causing 
inability  to perform usual 
social & functional 
activitie sDisabling visual loss in 
affected ey e(s)
2017N322544_01 CONFIDENTIA L
205820
89Systemic:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acute Allergic
ReactionLocalized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urtica ria with 
intervention indicated 
ORMild angioedema 
with no intervention 
indicatedGeneralized urticaria OR
Angioedema with 
intervention indicated OR
Symptoms of mild 
bronchospasmAcute anaph ylaxis ORLife-
threatening bronchospasm OR
Lary ngeal oedema
Chill s Symptoms causing no or 
minimal
interference with usual 
social & functional 
activitiesSymptoms causing 
greater than minimal 
interference with usual 
social &
functional activitiesSymptoms causing 
inability  to perform usual 
social & functional 
activitiesNot applicable
Cytokine Release
Syndrome 1Mild signs and sy mptoms 
AND Therap y (i.e., 
antibody  infusion) 
interruption not indicatedTherap y (i.e., antibod y 
infusion) interruption 
indicated AND
Responds promptly to 
symptomatic treatment 
ORProphy lactic 
medications indicated 
for ≤ 24 hoursProlonged severe signs and 
symptoms ORRecurrence 
of sy mptoms following 
initial improvementLife-threatening consequences 
(e.g., requiring pressor or 
ventilator support)
Fatigue or Malaise
Report only oneSymptoms causing no or 
minimal
interference with usual 
social & functional
activitiesSymptoms causing 
greater than minimal 
interference with usual 
social &
functional activitiesSymptoms causing 
inability  to perform usual 
social & functional 
activitiesIncapacitating s ymptoms of 
fatigue or malaise causing 
inability  to perform basic self -
care functions
2017N322544_01 CONFIDENTIA L
205820
90PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Fever (non-axillary  
temperatures only )38.0 to < 38.6°C or
100.4 to < 101.5°F3 8.6 to < 39.3°C
or 101.5 to
< 102.7°F39.3 to < 40.0°C or
102.7 to < 104.0°F40.0°C or 104.0°F
Pain 2(not associated with 
study  agent injections and 
not specified elsewhere)
Specify locationPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater 
than minimal 
interference with usual 
social & functional 
activitiesPain causing inabilit y to 
perform usual social
& functional activitiesDisabling pain causing 
inability  to perform basic self -
care functions OR
Hospitalization indicat ed
Serum Sickness 3 Mild signs and sy mptoms Moderate signs and 
symptoms AND
Intervention indicated 
(e.g., antihistamines)Severe signs and 
symptoms AND Higher 
level intervention 
indicated (e.g., steroids or 
IV fluids)Life-threatening consequences 
(e.g., requiring pressor or 
ventilator support)
Underweight 4
>5 to 19 y ears of age Not applicable WHO BMI z -score
< -2 to ≤ -3WHO BMI z -score
< -3WHO BMI z -score
< -3 with life -threatening 
consequences
2 to 5 y ears of age Not applicable WHO Weight -for-
height z -score
< -2 to ≤ -3WHO Weight -for-height 
z-score < 3WHO Weight -for-height z -
score < -3 with life -
threatening consequences
<2 years of age Not applicable WHO Weight -for-
length z -score
< -2 to -3WHO Weight -for-length 
z-score < -3WHO Weight -for-length z -
score < -3 with life -
threatening consequences
2017N322544_01 CONFIDENTIA L
205820
91PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Weight L oss (excludes 
postpartum weight
loss)Notapplicable 5 to < 9% loss in body  
weight from baseline≥9 to < 20% loss in body  
weight from baseline≥20% loss in body  weight 
from baseline OR Aggressive 
intervention indicated (e.g., 
tube feeding, total parenteral 
nutrition)
1.Definition: A disorder characterized b y nausea, headache, tach ycardia, h ypotension, rash, and/or shortness of breath.
2.For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section.
3.Definition: A disorder characterized b y fever, arthralgia, myalgia, skin eruptions, ly mphadenopathy , marked di scomfort, and/or 
dyspnoea
4.WHO reference tables may  be accessed by  clicking the desired age range or by  accessing the following URLs: 
http://www.who.int/growthref/who2007_bmi_for_age/en/ for participants >5 to 19 y ears of age and 
http://www.who.int/childgro wth/standards/chart_catalogue/en/ for those ≤ 5 y ears of age
2017N322544_01 CONFIDENTIA L
205820
92Urinary:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Urinary Tract
ObstructionNot applicable Signs or s ymptoms of 
urinary  tract obstruction 
without hy dronephrosis 
or renal d ysfunctionSigns or s ymptoms of 
urinary  tract obstruction 
with hy dronephrosis or 
renal d ysfunctionObstruction causing life -
threatening
consequences
2017N322544_01 CONFIDENTIA L
205820
93Site Reactions to Injections and Infusions:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Injection Site Pain or
Tenderness
Report only onePain or tenderness 
causing no or minimal 
limitation of use of limbPain or tenderness 
causing greater than 
minimal limitation of use 
of limbPain or tenderness causing 
inability  to perform usual 
social & functional 
activitiesPain or tenderness causing 
inability  to perform basic 
self-care function OR
Hospitalization indicated
Injection Site Erythema or 
Redness 1
Report only one
>15 years of age2.5 to < 5 cm in 
diameter OR 6.25 to 
<25 cm2surface area 
AND Symptoms causing 
no or minimal 
interference with usual 
social & functional 
activities5 to < 10 cm in 
diameter OR 25 to 
<100 cm2surface area
OR Sy mptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities10 cm in diameter OR
100cm2 surface area 
ORUlceration OR
Secondary  infection OR
Phlebitis ORSterile 
abscess ORDrainage OR
Symptoms causing 
inability  toperform usual 
social & functional 
activitiesPotentially  life-threatening 
consequences (e.g., abscess, 
exfoliative dermatitis, 
necrosis involving dermis or 
deeper tissue)
≤15 years of age ≤2.5 cm in diameter >2.5 cm in diameter with 
< 50% surface area of the 
extremity  segment 
involved (e.g., upper arm 
or thigh)50% surface area of the 
extremity  segment 
involved (e.g., upper arm 
or thigh) OR Ulceration 
ORSecondary  infection 
ORPhlebitis ORSterile 
abscess ORDrainagePotentially  life-threatening 
consequences (e.g., abscess, 
exfoliative dermatitis, 
necrosis involving dermis or 
deeper tissue)
2017N322544_01 CONFIDENTIA L
205820
94PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Injection Site
Induration or Swelling
Report only one
>15 years of ageSame a s for Injection 
Site Erythema or 
Redness, > 15 years of 
ageSame as for Injection 
Site Erythema or 
Redness, > 15 years of 
ageSame as for Injection 
Site Erythema or 
Redness, > 15 years of 
ageSame as for Injection Site 
Erythema or Redness, 
> 15 years of age
≤15 years of age Same as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
ageSame as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
ageSame as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
ageSame as for Injection Site 
Erythema or Redness, 
≤ 15 years of age
Injection Site Pruritus Itching localized to the 
injection site that is 
relieved spontaneously  
or in < 48hours of 
treatmentItching bey ond the 
injection site that is not 
generalized ORItching 
localized to the injection 
site requiring  48hours 
treatmentGeneralized itching 
causing inability  to 
perform usual social & 
functional activitiesNot applicable
1.Injection Site Ery thema or Redness should be evaluated and graded using the greatest single diameter or measured surface ar ea.
2017N322544_01 CONFIDENTIA L
205820
95Laboratory Values – Chemistries
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acidosis Not applicable pH 7.3 to < LLN pH < 7.3 without life -
threatening consequencespH < 7.3 with life -
threatening con sequences
Albumin, L ow
(g/dL; g/L)3.0 to < LLN
30 to < LLN2.0 to < 3.0
20 to < 30< 2.0
< 20Not applicable
Alkaline Phosphatase, High 1.25 to < 2.5 x UL N 2.5 to < 5.0 x UL N 5.0 to < 10.0 x UL N 10.0 x UL N
Alkalosis Not applicable pH > ULN to ≤ 7.5 pH > 7.5 without life -
threatening consequencespH > 7.5 with life -
threatening consequences
ALT or SGPT, High
Report only one1.25 to < 2.5 x UL N 2.5 to < 5.0 x UL N 5.0 to < 10.0 x UL N ≥ 10.0 x UL N
Amy lase (Pancreatic) or 
Amy lase (Total), High Report
only one1.1 to < 1.5 x UL N 1.5 to < 3.0 x UL N 3.0 to < 5.0 x UL N 5.0 x UL N
AST or SGOT, High
Report only one1.25 to < 2.5 x UL N 2.5 to < 5.0 x UL N 5.0 to < 10.0 x UL N 10.0 x UL N
Bicarbonate, Low
(mEq/L; mmol/L )16.0 to < LLN
16.0 to < LLN11.0 to < 16.0
11.0 to < 16.08.0 to < 11.0
8.0 to < 11.0< 8.0
< 8.0
2017N322544_01 CONFIDENTIA L
205820
96PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Bilirubin
Direct Bilirubin 1, High
>28 days of age Not applicable Not applicable >ULN >ULN with life -threatening 
consequences (e.g., signs 
and sy mptoms of liver 
failure)
≤ 28 days of age ULN to 1mg/dL >1 to 1.5mg/dL >1.5 to 2mg/dL >2mg/dL
Total Bilirubin, High
>28 days of age 1.1 to < 1.6 x UL N 1.6 to < 2.6 x UL N 2.6 to < 5.0 x UL N 5.0 x UL N
≤ 28 days of age See Section 12.4.1.  Total 
Bilirubin for Term and 
Preterm NeonatesSee Section 12.4.1.  
Total Bilirubin for Term 
and Preterm NeonatesSee Section 12.4.1.  
Total Bilirubin for Term 
and Pret erm NeonatesSee Section 12.4.1.  Total 
Bilirubin for Term and 
Preterm Neonates
Calcium, High
(mg/dL; mmol/L )
≥ 7days of age10.6 to < 11.5
2.65 to <2.8811.5 to < 12.5
2.88 to <3.1312.5 to < 13.5
3.13 to <3.3813.5
3.38
<7days of age 11.5 to < 12.4
2.88 to < 3.1012.4 to < 12.9
3.10 to < 3.2312.9 to < 13.5
3.23 to <3.3813.5
3.38
Calcium (I onized), High
(mg/dL ; mmol/L )>ULN to < 6.0
>ULN to < 1.56.0 to <6.4
1.5 to < 1.66.4 to < 7.2
1.6 to < 1.87.2
8
2017N322544_01 CONFIDENTIA L
205820
97PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Calcium, L ow
(mg/dL; mmol/L )
≥ 7days of age 7.8 to < 8.4
1.95 to < 2.107.0 to < 7.8
1.75 to < 1.956.1 to < 7.0
1.53 to < 1.75< 6.1
< 1.53
<7days of age 6.5 to < 7.5
1.63 to < 1.886.0 to < 6.5
1.50 to < 1.635.50 to < 6.0
1.38 to < 1.50< 5.50
< 1.38
Calcium (Ionized), Low
(mg/dL; mmol/L )<LLN to 4.0
<LLN to 1.03.6 to < 4.0
0.9 to < 1.03.2 to < 3.6
0.8 to < 0.9< 3.2
< 0.8
Cardiac Troponin I, High Not applicable Not applicable Not applicable Levels consistent with 
myocardial infarction or 
unstable angina as defined 
by the local laboratory
Creatine Kinase, High 3 to < 6 x UL N 6 to < 10 x UL N 10 to < 20 x UL N 20 x UL N
Creatinine, High 1.1 to 1.3 x UL N > 1.3 to 1.8 x UL N OR 
Increase of > 0.3 mg/dL 
above baseline>1.8 to < 3.5 x UL N OR 
Increase of 1.5 to < 2.0 x 
above baseline3.5 x UL N OR Increase of 
2.0 x above baseline
2017N322544_01 CONFIDENTIA L
205820
98PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Creatinine Clearance 2
or eGFR, L ow
Report only oneNot applicable <90 to 60 mL /min or 
mL/min/1.73 m2
OR
10 to < 30% decrease 
from baseline<60 to 30 mL /min or 
mL/min/1.73 m2
OR
30 to <50% decrease 
from baseline<30 ml/min or 
mL/min/1.73 m2
OR
50% decrease from 
baseline or dial ysis needed
Glucose
(mg/dL; mmol/L)
Fasting, High 110 to 125
6.11 to < 6.95>125 to 250
6.95 to < 13.89>250 to 500
13.89 to < 27.75> 500
27.75
Nonfasting, High 116 to 160
6.44 to < 8.89>160 to 250
8.89 to < 13.89>250 to 500
13.89 to < 27.75> 500
27.75
Glucose, Low
(mg/dL; mmol/L )
≥ 1 month of age55 to 64
3.05 to 3.5540 to < 55
2.22 to < 3.0530 to < 40
1.67 to < 2.22< 30
< 1.67
<1 month of age 50 to 54
2.78 to 3.0040 to < 50
2.22 to < 2.7830 to < 40
1.67 to < 2.22< 30
<1.67
Lactate, High ULN to < 2.0 x UL N 
without acid osis≥2.0 x UL N without 
acidosisIncreased lactate with 
pH< 7.3 without life -
threatening consequencesIncreased lactate with 
pH< 7.3 with life -
threatening consequences
Lipase, High 1.1 to < 1.5 x UL N 1.5 to < 3.0 x UL N 3.0 to < 5.0 x UL N 5.0 x UL N
2017N322544_01 CONFIDENTIA L
205820
99PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Lipid Disorders
(mg/dL; mmol/L )
Cholesterol, Fasting, High
≥ 18 years of age200 to < 240
5.18 to < 6.19240 to < 300
6.19 to < 7.77300
7.77Not applicable
<18 years of age 170 to < 200
4.40 to < 5.15200 to < 300
5.15 to < 7.77300
7.77Not applicable
LDL, Fasting, High
≥18 years of age 130 to < 160
3.37 to < 4.12160 to < 190
4.12 to < 4.90190
4.90Not applicable
>2 to < 18 years of age 110 to < 130
2.85 to < 3.34130 to < 190
3.34 to < 4.90190
4.90Not applicable
Triglycerides, Fasting, High 150 to 300
1.71 to 3.42>300 to 500
>3.42 to 5.7>500 to < 1,000
>5.7 to 11.4> 1,000
> 11.4
Magnesium 3, L ow
(mEq/L; mmol/L)1.2 to < 1.4
0.60 to < 0.700.9 to < 1.2
0.45 to < 0.600.6to <0.9
0.30 to < 0.45< 0.6
< 0.30
Phosphate, L ow
(mg/dL ; mmol/L )
>14 years of age 2.0 to < LLN
0.81 to < LLN1.4 to < 2.0
0.65 to < 0.811.0 to < 1.4
0.32 to <0.65< 1.0
< 0.32
1 to 14 years of age 3.0 to < 3.5
0.97 to < 1.132.5 to < 3.0
0.81 to < 0.971.5 to < 2.5
0.48 to < 0.81< 1.5
<0.48
2017N322544_01 CONFIDENTIA L
205820
100PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
<1 year of age 3.5 to < 4.5
1.13 to < 1.452.5 to < 3.5
0.81 to < 1.131.5 to < 2.5
0.48 to < 0.81< 1.5
<0.48
Potassium, High
(mEq/L; mmol/L )5.6 to < 6.0
5.6 to < 6.06.0 to < 6.5
6.0 to < 6.56.5 to < 7.0
6.5 to < 7.07.0
7.0
Potassium, L ow
(mEq/L; mmol/L )3.0 to < 3.4
3.0 to < 3.42.5 to < 3.0
2.5 to < 3.02.0 to < 2.5
2.0 to < 2.5< 2.0
<2.0
Sodium, High
(mEq/L; mmol/L )146 to < 150
146 to < 150150 to < 154
150 to < 154154 to < 160
154 to <160160
160
Sodium, L ow
(mEq/L; mmol/L )130 to < 135
130 to < 135125 to < 130
125 to < 135121 to < 125
121 to < 125120
120
Uric Acid, High
(mg/dL; mmol/L )7.5 to < 10.0
0.45 to < 0.5910.0 to < 12.0
0.59 to < 0.7112.0 to < 15.0
0.71 to < 0.8915.0
0.89
1.Direct bilirubin > 1.5mg/dL  in a participant < 28days of age should be graded as grade 2, if < 10% of the total bilirubin
2.Use the applicable formula (i.e., Cockroft -Gault in mL/min or Schwatrz in mL/min/1.73m2) 
3.To convert a magnesium value from mg/dL to mmol/L , laboratories should multiply  by 0.4114
2017N322544_01 CONFIDENTIA L
205820
101Hematology:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Absolute CD4+ Count, Low
(cell/mm3; cells/L )
>5 years of age
(not HIV infected)300 to < 400
300 to < 400200 to < 300
200 to < 300100 to < 200
100 to < 200< 100
<100
Absolute Lymphocyte
Count, Low
(cell/mm3; cells/L )
>5 years of age
(not HIV infected)600 to < 650
0.600 x 109to
<0.650 x 109500 to < 600
0.500 x 109to
<0.600 x 109350 to < 500
0.350 x 109to<0.500x109< 350
<0.350x109
Absolute Neutrophil
Count (ANC), Low
(cells/mm3; cells/L )
> 7days of age800 to 1,000
0.800 x 109to 
1.000 x 109600 to 799
0.600 x 109to 0.799 x 109400 to 599
0.400 x 109to 0.599 x 109< 400
<0.400 x 109
2 to 7 days of age 1,250 to 1,500
1.250 x 109to 
1.500 x 1091,000 to 1,249
1.000 x 109 to 1.249 x 109750 to 999
0.750 x 109to 0.999 x 109< 750
<0.750 x 109
≤1 day of age 4,000 to 5,000
4.000 x 109to 5.000 x 
1093,000 to 3,999
3.000 x 109to 3.999 x 1091,500 to 2,999
1.500 x 109 to 2.999 x 109< 1,500
<1.500 x 109
2017N322544_01 CONFIDENTIA L
205820
102PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Fibrinogen, Decreased
(mg/dL; g/L )100 to < 200
1.00 to < 2.00
OR
0.75 to < 1.00 x LLN75 to < 100
0.75 to < 1.00
OR
≥ 0.50 to < 0.75 x LLN50 to < 75
0.50 to < 0.75
OR
0.25 to < 0.50 x LLN< 50
<0.50
OR
<0.25 x LLN
ORAssociated with gross 
bleeding
Haemoglobin 1, Low
(g/dL; mmol/L ) 2
≥13 years of age
(male only)10.0 to 10.9
6.19 to 6.769.0 to < 10.0
5.57 to < 6.197.0 to < 9.0
4.34 to < 5.57< 7.0
< 4.34
≥ 13 years of age
(female only)9.5 to 10.4
5.88 to 6.488.5 to < 9.5
5.25 to < 5.886.5 to < 8.5
4.03 to < 5.25< 6.5
< 4.03
57days of age to <13 years of 
age
(male and female)9.5 to 10.4
5.88 to 6.488.5 to < 9.5
5.25 to < 5.886.5 to < 8.5
4.03 to < 5.25< 6.5
< 4.03
36 to 56 days of age
(male and female)8.5 to 9.6
5.26 to 5.997.0 to < 8.5
4.32 to < 5.266.0 to < 7.0
3.72 to < 4.32< 6.0
< 3.72
22 to 35 days of age
(male and female)9.5 to 11.0
5.88 to 6.868.0 to < 9.5
4.94 to < 5.886.7 to < 8.0
4.15 to < 4.94< 6.7
< 4.15
8 to ≤ 21 days of age
(male and female)11.0 to 13.0
6.81 to 8.109.0 to < 11.0
5.57 to < 6.818.0 to < 9.0
4.96 to < 5.57< 8.0
< 4.96
≤ 7days of age
(male and female)13.0 to 14.0
8.05 to 8.7210.0 to < 13.0
6.19 to < 8.059.0 to < 10.0
5.59 to < 6.19< 9.0
< 5.59
2017N322544_01 CONFIDENTIA L
205820
103PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
INR, High
(not on anticoagulation
therap y)1.1 to < 1.5 x UL N 1.5 to < 2.0 x UL N 2.0 to < 3.0 x UL N ≥ 3.0 x UL N
Methaemoglobin
(% haemoglobin)5.0 to < 10.0% 10.0 to < 15.0% 15.0 to < 20.0% ≥ 20.0%
PTT, High
(not on anticoagulation
therap y)1.1 to < 1.66 x UL N 1.66 to < 2.33 x UL N 2.33 to < 3.00 x UL N ≥ 3.00 x UL N
Platelets, Decreased
(cells/mm3; cells/L )100,000 to
< 124,999
100.000 x 109to
<124.999 x 10950,000 to
< 100,000
50.000 x 109to
<100.000 x 10925,000 to
< 50,000
25.000 x 109to
<50.000 x 109< 25,000
<25.000 x 109
PT, High
(not on anticoagulation
therap y1.1 to < 1.25 x UL N 1.25 to < 1.50 x UL N 1.50 to < 3.00 x UL N ≥ 3.00 x UL N
WBC, Decreased
(cells/mm3; cells/L )
> 7days of age 2,000 to 2,499
2.000 x 109to 
2.499 x 1091,500 to 1,999
1.500 x 109 to 1.999 x 1091,000 to 1,499
1.000 x 109to 1.499 x 109< 1,000
<1.000 x 109
≤ 7days of age 5,500 to 6,999
5.500 x 109to 
6.999 x 1094,000 to 5,499
4.000 x 109to 5.499 x 1092,500 to 3,999
2.500 x 109to 3.999 x 109< 2,500
<2.500 x 109
2017N322544_01 CONFIDENTIA L
205820
1041.Male and female sex is defined as sex at birth.
2.The conversion factor used to convert g/dL to mmol/L  is 0.6206 and is the most commonly  used conversion factor.  For grading 
haemoglobin results obtained by  an anal ytic method with a conversion factor other than 0.6206, the result must be converted to g/dL 
using the appropriate conversion factor for the particular laboratory .
2017N322544_01 CONFIDENTIA L
205820
105Urinalysis:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Glycosuria (random collection 
tested by  dipstick)Trace to 1+ or 250mg2+ or ˃250 to 500mg >2+ or > 500mg Not applicable
Haematuria (not to be reported 
based on dipstick findings or 
on blood believed to be of
menstrual origin)6 to < 10 RBCs per hig h 
power field≥10 RBCs per high
power fieldGross, with or without 
clots ORWith RBC casts 
OR Intervention indicatedLife-threatening 
consequences
Proteinuria (random collection 
tested by  dipstick)1+ 2+ 3+ or higher Not applicable
2017N322544_01 CONFIDENTIA L
205820
10612.4.1. Total Bilirubin Tab le for Term and Preterm Neonates:
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Total Bilirubin 1, High
(mg/dL; µmol/L ) 2
Term Neonate 3
<24 hours of age 4 to < 7
68.4 to < 119.77 to < 10
119.7 to <17110 to < 17
171 to <290.717
≥ 290.7
24 to <48 hours of age 5 to < 8
85.5 to < 136.88 to < 12
136.8 to < 205.212 to < 19
205.2 to < 324.919
324.9
48 to <72 hours of age 8.5 to < 13
145.35 to  <222.313 to < 15
222.3 to < 256.515 to < 22
256.5 to < 376.222
376.2
72 hour s to <7 days of age 11 to < 16
188.1 to < 273.616 to < 18
273.6 to < 307.818 to < 24
307.8 to < 410.424
410.4
7 to 28 days of age
(breast feeding)5 to < 10
85.5 to < 17110 to < 20
171 to < 34220 to < 25
342 to < 427.525
427.5
7 to 28 days of age
(not breast feeding)1.1 to < 1.6 x UL N 1.6 to < 2.6 x UL N 2.6 to < 5.0 x UL N 5.0 x UL N
Preterm Neonate20
35 to < 37 weeks gestational 
ageSame as for Total 
Bilirubin, High, Term 
Neonate (based on days of 
age).Same as for Total 
Bilirubin, High, Term 
Neonate (based on day s of 
age).Same as for Total
Bilirubin, High,
Term Neonate (based on 
days of age).Same as for Total 
Bilirubin, High, Term 
Neonate (based on day s of 
age).
32 to < 35 weeks gestational 
age and < 7 days of ageNot applicable Not ap plicable 10 to < 14
171 to < 239.414
239.4
2017N322544_01 CONFIDENTIA L
205820
107PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
28 to < 32 weeks gestational 
age and < 7 days of ageNot applicable Not applicable 6 to < 10
102.6 to < 17110
171
< 28 weeks gestational age 
and< 7days of ageNot applicable Not applicable 5 to < 8
85.5 to < 136.88
136.8
7 to 28 days of age (breast 
feeding)5 to < 10
85.5 to < 17110 to < 20
171 to < 34220 to < 25
342 to < 427.525
427.5
7 to 28 days of age (not 
breast feeding)1.1 to < 1.6 x UL N 1.6 to < 2.6 x UL N 2.6 to < 5.0 x UL N 5.0x UL N
1.Severity  grading for total bilirubin in neonates is complex because of rapidly  changing total bilirubin normal ranges in the first week of 
life followed b y the benign phenomenon of breast milk jaundice after the first week of life.  Severit y gradin g in this appendix 
corresponds approximately  to cut -offs for indications for phototherap y at grade 3 and for exchange transfusion at grade 4.
2.A laboratory  value of 1 mg/dL is equivalent to 17.1 mol/L .
3. Definitions: Term is defined as 37weeks gestational age; near -term, as 35weeks gestational age; preterm, as < 35weeks 
gestational age; and neonate, as 0 to 28 days of age.
2017N322544_01 CONFIDENTIA L
205820
10812.5. Appendix 5: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
12.5.1. Definition of A dverse Events
Adverse Event Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study  treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the Adverse Event Definition 
Any abnormal laboratory test result s (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the Investigator (i.e., not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed af ter stud y treatment administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of eith er study  
treatment or a concomitant medication.  Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent.  Such overdoses should be reported regardless of sequelae.
Events NO TMeeting the Adverse Event Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
Investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
2017N322544_01 CONFIDENTIA L
205820
109convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or c ondition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs /symptoms of the disease under study , 
death due to progression of disease).
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:
c.Results in death
d.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event.  I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
e.Requires inpatient hospitalization or prolongation of e xisting hospitalization
NOTE:
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriat e in the phy sician’s 
office or outpatient setting.  Complications that occur during hospitalization are AE.  
If a complication prolongs hospitalization or fulfills any  other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
f.Results in persistent disability/incapacity
NOTE:
The term di sability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, infl uenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
g. Is a congenital anomaly/birth defect
2017N322544_01 CONFIDENTIA L
205820
110h.Other situations:
Medical or scientific judgment should b e exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may  
jeopardize the participant or may  require medical o r surgical intervention to prevent 
one of the other outcomes listed in the above definition.  These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at h ome for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
i.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if 
unavailable, measure urinary  bilirubin via dipstick.  If fractionation is unavailable 
and ALT 3xUL N and total bilirubi n 2xUL N, then the event is still to be reported 
as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
participants receiving anticoagulants.  If INR measurement is obtained, the value is 
to be recorded on the SAE f orm.
Refer to Section 12.2, Appendix 2for the required liver chemistry  follow -up 
instructions
12.5.3. Recording A dverse Events and Serious A dverse Ev ents
Adverse Events and Serious Adverse Events Recording
When an AE/SAE occurs, it is the responsibility  of the Investigator to review all 
documentation (e.g., hospital progress notes, laboratory, and diagnostics reports) 
related to the event.
The Investigator will then record all relevant AE/SAE information in t he CRF.
It is notacceptable for the Investigator to send photocopies of the participant’s 
medical records to GSK in lieu of completion of the GSK /AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y GS K.  In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK.
The Investigator will attempt to establish a diagnosis of the event based on signs,
symptoms, and/or other clinical information.  Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
2017N322544_01 CONFIDENTIA L
205820
11112.5.4. Evaluating Adverse Events and Serious A dverse Ev ents
Assessment of Intensity
The Investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities.  An AE that is assessed as 
severe should not be confused with an SAE.  Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Asse ssment of Causality
The Investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a cau sal relationship, rather than a relationship cannot be 
ruled out.
The Investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temp oral relationship of the event to study  treatment 
administration will be considered and investigated.
The Investigator will also consult the Investigator ’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/ SAE, the Investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the Investigator has 
minimal information to include in the in itial report to GSK.  However, it is very 
important that the Investigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to GSK .
The Investigator may change his/her opinion of causality  in light of fo llow-up 
information and send an SAE follow- up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
2017N322544_01 CONFIDENTIA L
205820
112Follow -up of AE and SAE
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  GSK to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible.  This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
New or updated information will be recorded in the originally  completed CRF.
The Investigator will submit any  updated SAE data to GSK within 24 hours o f receipt 
of the information.
12.5.5. Reporting of Serious A dverse Events to GSK
SAE Reporting to GSK via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to GSK will be the electronic data 
collection tool.
If the electronic s ystem is una vailable for more than 24 hours, then the site will use 
the paper SAE data collection tool (see next section).
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The Investigator or medically -qualified sub -Investig atormust show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study  participation (causalit y) within 72 hours of SAE 
entry  into the eCRF.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE af ter the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see next 
section) or to the medical monitor by telephone.
Contacts for SAE reporting can be found in the SRM.
2017N322544_01 CONFIDENTIA L
205820
11312.6. Appendix 6 : Cont raceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
Women in the followin g categories are not considered WOCBP
7.Premenarchal
8.Premenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s: review o f participant’s 
medical records, medical examination, or medical history  interview.
9.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  A high follicle stimulating hormone (FSH) level in
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT).  However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y.  Otherwise, they  must discontinue HRT 
to allow confirmation of postm enopausal status before stud y enrollment.
Contraception Guidance
Male participants
Male participants with female partners of child- bearing potential are eligible to 
participate if they  agree to ONE of the following (during the protocol- defined 
time frame i n Section 6.1 ) :
Are abstinent from penile -vaginal intercourse as their usual and preferred 
lifesty le (abstinent on a long term and persistent basis) and agree to remain 
abstinent.
Agree to use a male condom plus an additional method of contraception 
with a failure rate of < 1% per y ear when having penile -vaginal intercourse 
with a woman of childbearing potential as described in Table 6.
2017N322544_01 CONFIDENTIA L
205820
114Men with a pregnant or breastfeeding partner must a gree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each episode of 
penile penetr ation (during the protocol-defined time frame).
Refrain from donating sp erm for duration of study and for 3 months after study 
completion or f rom last dose.
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in 
Table 6.
Table 6
Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly.
Combined (estrogen -and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulationb
oral
intravaginal
transdermal
Progestogen -only hormonal contraception associated with inhibition of ovulationb
injectable
Highly Effective Methods That Are User Independent 
Implantable progestoge n-only hormonal contraception associated with inhibition of 
ovulationb
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.) 
Sexual abstinence 
(Sexual abstinence is considered a hig hly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and 
the p referred and usual lifestyle of the participant) .
2017N322544_01 CONFIDENTIA L
205820
115NOTES: 
a. Typical use failure rates may differ from those when used consistently and correctly.  Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants in clinical studies. 
b. Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method.  In this case two highly effective methods of contraception should be utilized during the 
treatment period and for at least 30 days, 5 half -lives or twice the duration of the biological effect of the 
investigational product (whichever is longer)  after the last dose of study treatment 
Pregnancy  Testing
WOCBP should only  be included after a confirme d menstrual period and a negative 
highl y sensitive urine or serum pregnancy  test 
Additional pregnancy  testing may  be performed at the discretion of the Investigator
during the treatment period or after the last dose of study  treatment and as required 
locally.
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected.
Pregnancy  testing will be performed using the test kit provided by  the central 
laboratory .
Collection of Pregnancy  Information
Male part icipants with partners who become pregnant
Investigator will attempt to collect pregnancy  information on any  male participant’s 
female partner of a male study  participant who becomes pregnant while participating 
in this study .  This applies only  to partici pants who receive study  treatment.
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the Investigator will record pregnancy  information on the 
appropriate form and submit it to GSK within 24 hours of learning of the partner’s 
pregnancy .
Partner will also be followed to determine the outcome of the pregnancy .  
Information on the status of the mother and child will be forwarded to GSK.
Generally , follow -up will be no longer than 6 to 8 weeks following the estimat ed 
delivery  date.  An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure.
Female Participants who become pregnant
Investigator will collect pregnancy  information on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to GSK within 
24hours of learning of a participant's pregnancy . 
Participant will be followed to determine the o utcome of the pregnancy .  The 
Investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK Generall y, follow- up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.
2017N322544_01 CONFIDENTIA L
205820
116Any terminat ion of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy wil l be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  the Investigator , will be reported to 
GSK. While the Investigator is not obligated to actively  seek this information in 
former stud y participants, he or she may learn of an SAE through spontaneous 
reporting.
Any female participant who becomes pregnant while participating w ill be withdrawn 
from the study .
2017N322544_01 CONFIDENTIA L
205820
11712.7. Appendix 7: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines.
Applicable ICH Good Clinical Practice (GCP) Guidelines.
Applicable laws and regulations.
The protocol, protocol ame ndments, I CF, Investigator Brochure, and other 
relevant documents (e.g., advertisements) must be submitted to an I RB/IEC by  
the Investigator and reviewed and approved b y the I RB/IEC before the study  is 
initiated.
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants.
The Investigator will be responsible for the following:
Providing written summaries of the sta tus of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  the IRB/EC.
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures.
Provid ing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
Financial Disclosure
Investigators and sub- Investigator s will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory au thorities.  
Investigator s are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
Informed Consent Process
The Investigator or his/her representative will explain the nature of the study  to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study .
Participants must be informed that their participation is voluntary .  Participants 
or their legally authorized representative will be required to sign a statement of 
2017N322544_01 CONFIDENTIA L
205820
118informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability  and Accountability  Act (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center.
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained . The authorized person obtaining the informed consent 
must also sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study .
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative.
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  the Sponsor.  Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be 
used by  the sponsor in accordance with local data protection law.  The level of 
disclosure must also be explained to the participant.
The participant must be informed that his/her medical records may  be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appointed 
by the sponsor, b y appropriate IRB/IEC members, and by  inspectors from 
regulatory  authorities.
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission.
  This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results.  
In accordance with standard editorial and ethical practice, the sponsor will 
generall y support publication of multicenter studies only  in their entiret y and not 
as individual site data. In this case, a coordinating Investigator will be 
designated b y mutual agreement.
Authorship will be determined by  mutual agreement and in line with 
Internati onal Committee of Medical Journal Editors authorship requirements.
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g., 
2017N322544_01 CONFIDENTIA L
205820
119laborator y data).  The Investigator is responsible for verify ing that data entries 
are accurate and correct by  physically  or electronically  signing the CRF.
The Investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF.
The Investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data.
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by  the Investigator for 25 years from the issue of the final 
Clinical Study  Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period.  No records may  be 
destroy ed during the retention period without the written approval of the 
sponsor.  No records may  be transferred to another location or part y without 
written notification to the sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
Investigator ’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained.  The Investigator may need to request previous 
medical records or transfer records, depending on the study .  Also, current 
medical records must be available.
Study and Site Closure
GSK or it s designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of GSK. Study  sites will be closed upon study  
completion.  A study  site is considered closed when all required documents and stud y 
supplies have been collected and a stud y-site closure visit has been performed.
The Investigator may initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or Investigator may include 
but are not limited to:
2017N322544_01 CONFIDENTIA L
205820
120Failure of the Investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GC P 
guidelines.
Inadequate recruitment of participants by  the Investigator .
Discontinuation of further study  treatment development.